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This thesis describes novel contributions to scientific knowledge in the areas of 
non-protein coding RNA (ncRNA) and pathological angiogenesis. In the last 15 
years a number of studies have sought to identify potential markers of tumour 
endothelium. However, as of yet, no studies have identified non-protein markers of 
the tumour vasculature. These ‘phantoms of transcription’ encompass diverse 
classes that have long been thought to be merely ‘junk’, but some have recently 
been attributed novel functionality. 
The data used to identify non-protein markers of the tumour vasculature in 
this study was obtained through the RNA sequencing (RNAseq) of tumour 
endothelial cells (TEC) and healthy tissue associated endothelial cells (HEC). The 
ensuing bioinformatic analysis revealed many differentially expressed short 
nuclear RNA (snoRNA) and long intergenic ncRNA (lincRNA) molecules. Some of 
which were confirmed as being specifically expressed in (and differentially 
expressed between) TEC and HEC using quantitative PCR (qPCR). 
 One of these molecules, PCAT19, was also functionally explored in 
vitro. This study demonstrated that PCAT19 was specifically expressed in 
endothelial cells and expressed at lower levels in TEC than HEC (a tumour 
suppressor-like expression pattern). Moreover PCAT19 was shown to affect the 
cell cycle in vitro at G1 and G2/M, and cause increased levels of apoptosis. 
Microarray technology was used to reveal the mechanism by which affects the 
transcriptome of endothelial cells. Through this means a known regulator of 
tumour suppressors, CBX5 (Chromobox protein homolog 5), was demonstrated to 
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be co-expressed with PCAT19, following the knockdown and overexpression of 
PCAT19. PCAT19 is the first ncRNA molecule to be identified as both specific to 
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Chapter 1: Introduction 
The overall aim of the research projects detailed in this thesis was to identify non-
protein coding RNA markers within endothelial cells, which compose the innermost 
layer of blood vessels. The acquisition of a vasculature is a fundamental 
component leading to the formation of solid tumours (1) and has been investigated 
as a possible anti-cancer target for nearly half a century (2,3). Folkman (2) was the 
first to propose the concept of an anti-angiogenic therapy, which could prevent 
tumour growth by stopping the penetration of new blood vessels. Hence, the 
overarching dogma of such anti-angiogenic therapies is that a tumour will die once 
it has been denied the nutrients and oxygen provided by the blood vessels within it. 
In 1993 Burrows and Thorpe (4) were the first to demonstrate that it was 
possible to achieve an anti-cancer effect by targeting tumour-associated blood 
vessels in mice. This proof of principle was achieved by utilising subcutaneous 
neuroblastoma cells expressing murine interferon γ (γIFN). The γIFN induced an 
inflammatory response in the tumour vasculature and caused the expression of 
major histocompatibility complex (MHC) class II antigens. An anti-cancer effect 
was then achieved through the use of ricin-A chain conjugated anti-mouse class II 
antibodies, which caused haemorrhaging, necrosis and subsequently tumour 
regression. This study raised the possibility that a therapeutic agent could target 
cancer should a suitably specific target be found within the tumour-associated 
vasculature. 
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Targeting tumour-associated endothelial cells is a particularly attractive 
strategy because they have direct and intimate contact with the blood and are 
therefore accessed comparatively easily by therapeutic agents (5). The specificity 
of anti-angiogenic strategies is also an advantage over traditional 
chemotherapeutic agents. Chemotherapeutic agents target both cancerous and 
normal cells, which results in a narrow therapeutic window and severe side effects 
(6). For these reasons, many anti-angiogenic strategies have been explored in 
clinical trials (Table 1.1). 
 
Table 1.1: Anti-angiogenic therapies used in clinical trials 
The anti-angiogenic therapies in this table have all been investigated in clinical trials and in a 
variety of tumour types (7). 
 
Type Drug Target






Apatinib VEGFR2, RET, c-KIT, c-SRC
Axitinib VEGFR, PDGFR
BIBF 1120 VEGFR, PDGFR, FGFR




Foretinib VEGFR, c-MET, FLT3, c-KIT
Linifanib VEGFR, PGDFR, FLT1, FLT3, CSF-1R, c-KIT
MetMab c-MET
Pazopanib hydrochloride VEGFR, PGDFR, c-KIT
Sunitinib malate VEGFR, PGDFRb, FLT3, CSF-1R, c-KIT
Sorafenib tosylate VEGFR, PDGFR, c-KIT, RAF
Vandetanib VEGFR2, EGFR
Vatalanib VEGFR2, EGFR
XL184 VEGFR, c-MET, RTK, FLT3, TIE2






Receptor tyrosine kinase inhibitors
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1.1 Characteristics of healthy tissue and tumour associated 
endothelial cells. 
There are multiple precipitating factors that induce transcriptional changes within 
tumour-associated endothelial cells. Many of these differences are caused by the 
microenvironmental changes that occur during the progression of healthy tissues 
towards that of a cancerous nature (8, 9, 10). The blood vessels contained within 
solid tumours are structurally abnormal. This in turn leads to convoluted blood flow 
that is impeded due to an absence of the conventional hierarchical organisation 
between arteries, veins and capillaries (10). The resulting hypoxia, low pH (11, 12) and 
low shear stress (13) fundamentally alters the RNA and protein repertoires with 
endothelial cells. 
However transcriptional differences can be induced by more subtle changes 
within the endothelial cells themselves, such as the switch from quiescence to an 
actively angiogenic phenotype (14). An excessively angiogenic phenotype within 
endothelial cells is promoted by tumours due to the excess secretion of factors 
including Vascular Endothelial Growth Factor (VEGF), which is a significant 
regulator of angiogenesis leading to capillary sprouting (Figure 1.1) (15, 16). 
The process by which existing blood vessels form new blood vessels is 
termed angiogenesis. Angiogenesis is an essential component of normal 
development and wound healing. Conversely the mechanisms involved with 
angiogenesis can be hijacked and act as precipitating factors in the etiology of 
many diseases. Endothelial cells in particular contribute to the pathological 
processes involved with cancer through the aforementioned angiogenic 
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mechanisms. But whilst an ever-increasing number of molecular changes have 
been identified, many probably remain as yet undefined (9, 15-18). 
 
Figure 1.1: Angiogenic sprouting and blood vessel growth 
Angiogenic stimuli can cause the differentiation of endothelial cells to form tip cells. Tips cells 
digest and migrate through the basement membrane towards the angiogenic stimuli. In the wake of 
these tip cells neighbouring endothelial cells proliferate and assemble to form capillary-like sprouts 
(19). The newly formed sprouts extend and eventually fuse with other blood vessels (or themselves) 
to establish blood flow (original diagram). 
 
1.2 Potential functionality for ncRNA in tumour-associated endothelial 
cells 
In man, there are approximately 20,000 expressed genes are encoding within a 
mere 1.5% of the DNA and the rest has long been thought to be junk (20-21). It is 
curious that organisms as far apart on the evolutionary scale such as C. 
(Caenorhabditis) elegans and man have similar numbers of expressed genes, and 
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the difference in their genomes lies in the amount of ‘junk’ DNA (26% in C. elegans 
versus 98.5% in man) (21). Some schools of thought are of the opinion that therein 
lies one explanation for the increase in complexity. For example, we now know 
that a vast amount of this ‘junk’ DNA is transcribed and contains many regulators 
of the expression of the transcribed genes and transcribed pseudogenes (20). 
These include microRNA (miRNA) and anti-sense RNA as well as more 
‘established’ non-coding RNAs such as ribosomal RNA (rRNA) (22). Currently there 
are about 75,000 transcripts in the reference genome that have been annotated as 
being non-coding RNAs, comprising of ~800 snoRNA (short nucleolar RNA), 
~80,000 lncRNAs (Long non-coding RNAs), ~4,500 miRNAs, 4000 rRNAs and 
~1,250 tRNAs (transfer RNA) (23). 
 miRNA typically ranges in size from about 21 to 23 nucleotides. Their 
primary function appears to be the post-transcriptional regulation of target genes 
and they do this by binding to complementary or partially complementary 
messenger RNA (mRNA) sequences, typically in the three prime untranslated 
region (3’ UTR). The silencing activity of miRNA is achieved by utilising the RNA 
induced silencing complex (Figure 1.2). If the miRNA is partially complementary to 
the mRNA target translation will be blocked, however if their sequences are fully 
complementary the mRNA will be degraded (24-26). 
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Figure 1.2: Mature miRNA production and RISC assembly 
Primary miRNA (Pri-miRNA) can be expressed from a variety of transcripts including miRNA cluster 
host genes, the three prime untranslated regions (3’ UTR) of protein coding genes and from within 
the introns of protein coding genes after splicing has occurred. The pre-miRNA is cleaved from the 
pri-miRNA by the enzyme Drosha based upon the shape of miRNAs hairpin loop. The pre-miRNA 
is then exported to the cytoplasm where Dicer can further process it into mature miRNA. The 
mature miRNA can then be used to modulate mRNA expression once Argonaute 2 (AGO2) has 
assimilated it into the RNA-induced silencing complex (RISC). RNA is most often targeted by 
miRNA downstream from the open reading fame (ORF), in the 3’ UTR. If the miRNA is fully 
complementary to the target sequence the RISC will degrade the mRNA. If the miRNA is only 





















lncRNA or ‘phantoms’ are characterised as having sequences that resemble 
genes, but have been traditionally thought to be biologically inconsequential. This 
assumption was made because of the presence of truncating mutations, 
frameshifts and other mutations that would not allow for translation into functional 
proteins. However, there is evidence that pseudogenes are transcribed into 
“phantom mRNA” and that these non-protein coding RNAs could have roles within 
the cell. This theory is supported by the high degree of conservation of nucleotide 
sequences within pseudogenes, showing that a selective pressure is placed on 
these genes. The transcription of pseudogenes can be tissue-specific and 
activated in cancer, suggesting that the expression of phantom mRNA could have 
a significant impact on angiogenesis and carcinogenesis. Nevertheless. few 
pseudogenes have been functionally characterised (22; 24; 27). 
 The pseudogene PTENP1 (Phosphatase and Tensin Homolog Pseudogene 
1) is a good example of this action as its transcript acts as a decoy for mRNA of 
the PTEN (Phosphatase and Tensin Homolog) tumour suppressor gene and 
allows for the expression of PTEN to occur in the presence of miRNAs (Figure 1.3). 
PTENP1 is derived from a retrotranscription event, but has a mutated start codon, 
which stops the mRNA from being translated into a protein. Despite being a 
truncated form of PTEN, PTENP1 contains five conserved sites for miRNA in its 3’ 
untranslated region. The decoy effect of phantom mRNA appears to be essential 
in maintaining the activity of PTEN and reducing tumourgenicity, the knockout of 
PTENP1 is associated with a decrease of PTEN mRNA and protein levels, which 
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in turn results in accelerated cell proliferation and cancer through the Akt/PKB 
signaling pathway (24, 28). 
 
 
Figure 1.3: The role of PTENP1 as a molecular decoy and tumour suppressor 
The pseudogene, PTENP1, shares a large part of the three prime (3’) untranslated region (UTR) of 
the protein-coding gene, PTEN. Any miRNAs capable of degrading PTEN will also be capable of 
degrading PTENP1 via the RISC, providing the two transcripts share a similar target region. 
miRNAs such as miRNA21 will be capable of degrading both PTEN and PTENP1, but PTEN is less 
likely to be degraded if PTENP1 is expressed (due to miRNA binding site competition). Therefore 
when the expression of PTENP1 is reduced, PTEN is more likely to be degraded (original diagram). 
 
PTENP1!
MIR21 meditated degradation 
of PTENP1 by RISC!
PTENP1!
PTENP1 is unable to function 
as a competing endogenous 
RNA (miRNA sponge)!
PTEN!
Translation of PTEN and 
negative regulation of the 
ATK/PKB pathway!
PTEN!
MIR21 meditated degradation 
of PTEN by RISC and 
deregulation of the ATK/PKB 
pathway!
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 It is important to note that phantom mRNAs do not just act as miRNA 
sponges; they could have many other functions. A recent article by Han et al. (27) 
highlights one of these possible functions, when the pseudogene MYLKP1 
(myosin light chain kinase pseudogene 1) is overexpressed it can inhibit smMLCK 
(smooth muscle myosin light chain kinase) by decreasing RNA stability, however 
the precise enzymatic mechanism is not yet known. But it has been suggested that 
a 5’ (five prime) UTR acting RNA-destabilizing factor could be responsible (29). 
 Like protein coding genes, non-coding RNAs (ncRNAs) appear to have 
tissue-specific profiles. It is possible that some endothelial or tumour endothelial-
specific ncRNAs exist. McCall et al. (30) demonstrated that 6 different endothelial 
cell types had different miRNA expression profiles. Furthermore they 
demonstrated that 31 miRNAs were possibly unique to the endothelium by 
comparing the 166 miRNA expressed in endothelial cells to epithelial and 
haematologic cells. It is therefore possible that endothelial cells specifically 
express transcripts from the other ncRNA classes, such as lncRNA and snoRNA. 
 
1.3 Past methods for the identification of tumour endothelial cell 
markers 
In 2000 Huminiecki and Bicknell (31) combined two data mining approaches, which 
led to the identification of sixteen genes that were specifically expressed in 
endothelial cells, including four previously unidentified (novel) genes. A high 
stringency BLAST was used to screen a pool of nine human endothelial cell 
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libraries against the ‘UniGene gene index’ and 108 non-endothelial libraries 
derived from the ‘Expressed Sequence Tags database’ (dbEST). 
 The second approach utilised internet-based (SAGEmap exprofiler) SAGE 
(serial analysis of gene expression) library subtraction. However, cross-
referencing between the expressed sequence tag (EST) and SAGE library 
analyses was required to accurately identify genes preferentially expressed in 
endothelial cells. Individually the two methods produced large numbers of false 
positives. 
 The study by Huminiecki and Bicknell (31) was not aimed at identifying 
specific markers of the tumour-associated endothelium. However, some of the 
publically available endothelial cell libraries included actively angiogenic cells, 
such as HUVEC (human umbilical vein endothelial cells). One of the four novel 
genes, ROBO4 (roundabout, axon guidance receptor, homolog 4), was later 
shown by Huminiecki et al. (32) to be specific to the tumour-associated endothelium 
and play a role in angiogenic processes, such as endothelial cell migration (33). 
Furthermore, anti-angiogenic (and therefore anti-cancer) therapies against ROBO4 
have been explored via in vivo vaccination by Zhuang et al. (34) and drug 
conjugated anti-ROBO4 antibodies by Yoshikawa et al. (35). 
 A method was later developed by the Herbert et al. (36, 37) to reduce the false 
positive rate associated with their earlier study. The complementary DNA (cDNA) 
data mining method utilised improved statistical analysis and an assignment of 
ESTs. These improvements allowed the identification of a further fourteen genes 
that were specifically expressed in endothelial cells. This method also predicted 
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‘one hundred and sixty’ genes to be upregulated in endothelial cells. When 
combining this method with the SAGEmap xProfiler, the list was expanded to 
include the accurate prediction of 58 genes that were specific to endothelial cells 
and a further 459 upregulated genes. Finally, a list of 27 potential tumour 
endothelial restricted genes was predicted by subtracting bulk tumour cDNA 
libraries from healthy tissue libraries. 
 The two previously described studies were both able identify genes that 
were expressed specifically in the tumour-associated endothelium. However they 
had one overarching disadvantage in this respect. The publically available libraries 
were all derived from healthy endothelial cells, albeit sometimes foetal and 
therefore actively angiogenic. 
St. Croix et al. (8) were able to overcome the disadvantage of these studies 
and identify a number of markers in the tumour-associated endothelium. The 
generation of two SAGE libraries from purified healthy colon associated 
endothelial cells and colorectal tumour-associated endothelial cells enabled this. 
When assembled, the SAGE tags generated roughly 32,703 unique transcripts 
(after the exclusion of repetitive tags). It was by comparing these transcripts to 
SAGE libraries from non-endothelial sources that St. Croix et al. (8) were able to 
identify 93 transcripts that were a minimum of twenty-fold higher in endothelial 
cells. But the key part of this study was the comparison of the healthy tissue and 
colorectal tumour-associated endothelial cell libraries. A minimum of ten-fold 
higher expression was observed in 46 tags from the colorectal tumour-associated 
endothelial cell library. Of the top 25 tags, eleven corresponded to known genes (6 
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were known markers of endothelial cells at the time) and the remaining 14 tags 
were derived from areas of the genome that were not yet known to be genes. Nine 
of these tags were confirmed to be specific to the tumour-associated endothelium 
by in situ hybridisation. 
 Many of the tumour-associated endothelial cell markers from this study 
have been the subject of further research as potential anti angiogenic therapies. 
Including TEM8, the anthrax toxin receptor 1. TEM8 has been targeted for the 
treatment of numerous tumour types in vivo using antibodies (38) and even using 
modified forms of the anthrax toxin (39, 40). 
 The studies conducted by Huminiecki and Bicknell (31), Herbert et al. (36, 37) 
and St. Croix et al. (8), demonstrate the ability for EST libraries to successfully 
identify endothelial cell-specific and tumour endothelial cell-specific genes. 
However, these libraries are generally constructed using SAGE, CAGE (cap 
analysis of gene expression) and MPSS (massively parallel signature sequencing). 
These methods utilise ‘Sanger sequencing’ and therefore are very labour intensive, 
low throughput and often prohibitively expensive. This reduces the feasibility of 
producing new EST data if the existing libraries are not sufficient to answer a 
hypothesis or to control for biological and technical variability. Conjointly, even 
should public libraries exist, there is no guarantee that they have been sequenced 
at a sufficient depth to enable the detection of biologically important transcripts 
that are expressed at low levels. Furthermore the tags produced by these 
technologies are very short and are often not able to span repetitive elements in 
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the genome. For this reason, it can also be extremely difficult to distinguish 
between splice variants (41-43). 
Microarrays were utilised by Zhang et al. (14) and Ghilardi et al. (44) as a high 
throughput alternative method to probe the transcriptome of endothelial cells. The 
aim of both these studies was to reveal the transcriptional differences within 
endothelial cells. The former utilised quiescent and proliferative (exposed to 
growth factors such as VEGF) foreskin microvascular endothelial cells. Whereas 
the latter used endothelial cells that were isolated from a number of healthy and 
cancerous tissues. Ho et al. (45) utilised microarray technology to compare four 
types of endothelial cells to five non-endothelial cell types and successfully 
identified several previously unknown endothelial-specific genes. These studies all 
used microarray technology that was relatively advanced at the time. However, 
they were severely limited by the number of probes used and targeted 588 (14), 
12,000 (44), 672 (45) genes respectively. 
Ultimately the targeted nature of microarray technology means that it can 
provide data in a manner that is more cost effective and less labour intensive 
when compared to SAGE libraries. Notwithstanding this fact, SAGE libraries 
produce superior data. SAGE libraries are not limited by the number/variety of 
probes, as even the most advanced microarrays currently available can’t detect 
areas of the genome that they are not designed to detect (such as unknown genes, 
repetitive regions or areas perceived to not be important) (43). A further 
disadvantage of microarrays is that the data comes in the form of continuous 
measures (fluorescent fold change to a reference), rather than absolute values 
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(raw read counts). This feature makes it very difficult to compare data across 
experiments and determine which genes have a relevant expression pattern (42).  
Endothelial cells have long been thought to be among the most 
transcriptionally rich cell types (46-48), and it is indeed true that many endothelial-
specific genes have been discovered (Table 1.2). However, RNA sequencing 
(RNAseq) could reveal many more biologically interesting genes and ncRNAs that 
were missed by these studies. These genes could be identified not just because of 
the advantages of RNAseq over the SAGE and microarrays (as discussed in 
Section 1.4), but also by screening the transcriptome of healthy and tumour 
endothelium derived from different organ/tissue types. The support for this 
predicted diverse gene expression pattern derives from the requirement of 
endothelial cells to adapt to varying blood flow, pressure and microenvironments, 
and accommodate the needs of individual tissues (46-48). 
Through a global gene expression analysis of 53 different endothelial cell 
types using microarrays, Chi et al (46) demonstrated that endothelial cells derived 
from large vessels had pervasive gene expression differences when compared to 
microvascular associated endothelial cells, and characteristic expression gene 
expression profiles in endothelium of arterial and venous sources. Moreover, Chi 
et al (46) identified that endothelial cells from different organs have distinct gene 
expression profiles, which raises the possibility that ncRNAs could be expressed 




Table 1.2: Known potentially endothelial-specific genes 
The genes in this table have been predicted to be endothelial-specific using SAGE and microarray 
analysis. It is important to note that many of these genes may have little/no utility as anti-
angiogenic targets due to being highly expressed by the healthy vasculature, or because of a non-
angiogenic function (such as platelet adherence). On the other hand, the function of the gene is 
irrelevant when using anti-endothelial cell therapies, because the therapy is designed to kill the cell, 
rather than inhibit a specific function. 
 
1.4 Whole transcriptome shotgun sequencing of the tumour 
endothelium 
RNAseq uses technology that is known by many names: next (or 2nd/3rd) 
generation sequencing, deep sequencing and whole transcriptome shotgun 
Gene Ref. Gene Ref. Gene Ref. Gene Ref.
ANG 8 EMCN 36, 45 MMRN1 31, 36, 45 RAMP2 31
ANGPT2 31,45 ERG 36 MYCT1 36, 45 RAPGEF3 36
ARHGAP24 36 ESM1 45 NESH 8 RASIP1 31, 45
ARHGEF15 36 FABP4 31 NOD27 36 RHOJ 36, 45
BMP1 45 FAM124B 36 NOSTRIN 36 ROBO4 31, 36, 45
BMX 36 FGD5 31, 45 NTN4 8 S14L1 45
CALCRL 36 FZD4 36 PAK2 45 S1PR1 45
CD34 36 GIMAP6 36 PALMD 45 SDPR 45
CD93 31, 36, 45 GIMAP7 45 PCDH12 36 SEC14L1 45
CDH5 31, 36, 45 GNA11 8 PECAM1 31, 45 SELE 36
CLEC14A 45 HHIP 36, 45 PEM1 8 SERPINE1 45
COLIVA1 31 ICAM2 45 PEM2 8 SHE 45
COLIVA2 8 IFITM1 8 PEM3 8 SLC35A2 36
COLV1A1 8 IGFBP4 8 PEM5 8 SMURF2 36
COLVIA2 8 IL33 36 PEM6 8 SOX7 36
COLXVIIIA1 8 KDR 45 PEM7 8 SPARC 8
CRP2 8 LAMA4 45 PEM9 8 SPARCL1 8, 36
CTGF 8, 45 LDB2 45 PLA2G4C 36 SRPX 36
ECSCR 31, 36, 45 LPHN1 8 PLSCR4 45 TCF4 36, 45
ECSM1 31 MCAM 8, 45 PODXL 45 THBS1 45
EDG1 36 MCF2L 8 PPP1R16B 45 TMSB4X 45
EDN1 31, 45 MFNG 45 PRKACA 45 TNS2 8
EFEMP1 31, 45 MGP 8, 45 PROCR 45 VWF 8, 31, 36, 45
ELTD1 36, 45 MMP1 36 RAD54L2 36 ZNF521 45
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sequencing (WTSS). These names all hint at the nature of the technology being 
used. RNAseq has the ability to deliver data regarding the whole transcriptome 
and this data comes in the form of discrete counts (the frequency of a specific 
sequence) known as reads. Once the reads are sequenced they can be aligned to 
a reference to determine which genes were present in a sample (Figure 1.4, 1.5 
and 1.6). RNAseq has the strengths associated with both SAGE and microarray 
analysis. It shares the high throughput and economical advantages of microarrays 
and the significant advantages of SAGE (as discussed earlier). RNAseq data also 
allows for information regarding the expression of individual genes to be 
determined easily. Namely whether the genes of interest are differentially 
expressed, abundant or completely absent (42, 49). Moreover the vast number of 
reads produced across the full length of transcripts allows for splice variant and 
novel transcripts to be more easily identified, quantified and validated (43). 
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Figure 1.4: The theory behind mapping reads 
The process of sequencing and mapping WTSS data is essentially akin to taking thousands of 
copies of ‘A Tale of Two Cities’ by Charles Dickens, shredding them into millions of small chunks 
(reads) (A) and aligning the shredded reads to a complete version to reconstruct the books (B). 
The process of mapping reads to a reference is somewhat easier and computationally less 
intensive than assembling a genome. Genome assembly necessitates the reassembly of reads by 
comparing the overlapping sections of the reads to reform the book without a reference (original 
diagram). 
It was the best of times, it was the worst of times 
It was the be 
orst of times 
, it was the w 
best of times 
the best of ti 
times, it was t 
the worst of ti 
It was the best of times, it was the worst of times 
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Figure 1.5: Mapping of RNAseq data to a reference genome 
The alphameric files (refer to Figures 1.4 and 3.2) generated through the analysis of sequenced 
and fragmented cDNA are bioinformatically re-constructed and compared to a reference genome. 
The overlapping areas between the reads allow for individual RNA molecules to be deciphered and 
quantified. The overlapping regions and gaps ultimately allow for the identification of exon-intron 
boundaries and even the characterisation of splice variants (original diagram). 
 
 
Figure 1.6: Reads that map to multiple areas of the genome 
Individual reads can sometimes be difficult to assign to the genome if it contains a repetitive or non-
unique sequence. It is more likely for longer reads to span these regions. But this problem can be 
partially negated using paired-end sequencing on short read platforms, where two reads are 
produced from each end of a cDNA fragment. The location of a paired read can give information 
regarding the location of a non-unique read and reduce the number of reads discarded (original 
diagram). 
 
Exon 3!Exon 1! Exon 2!




There are many deep sequencing platforms currently available. At the most 
basic level the difference between 2nd and 3rd generation platforms is the ability for 
the latter to detect the nucleotide sequence directly (i.e. without fluorescence) and 
without polymerase chain reaction (PCR) amplification. Illumina and SOLiD 
(sequencing by oligonucleotide ligation and detection) are the most commonly 
used 2nd generation platforms, whereas Ion Torrent, Pacbio and Nanopore are all 
3rd generation platforms. The Illumina and SOLiD platforms were used to generate 
the data in this thesis, their chemistry and relative strengths and weaknesses will 
be discussed at length throughout Chapters 2, 3, 4 and 5. However, the chemistry 
and relative strengths and weaknesses of the 3rd generation platforms are beyond 
the scope of this thesis (these platforms produce smaller amounts/depths of very 
long reads that are better suited to genomics, rather than RNAseq), but the 
following reviews by Liu et al. (49), Branton et al. (50), Mardis (51) and Glen (52) 
provide a good introduction.  
Ultimately the first step in achieving accurate insights into the expression 
profiles of endothelial cells within tumours or healthy tissues necessitates the 
robust and reproducible isolation of endothelial cells (Figure 1.7). But the choice of 
sequencing platform and experimental protocol is also critical to the success of the 
project. Of the aforementioned platforms SOLiD and Illumina were chosen to 
perform the sequencing in this thesis. This is largely due the current technological 
trade off between the long reads lengths required to span repeats and high 
sequencing depths required to identify less abundant transcripts, of which the 
hindmost was deemed to be more crucial. 
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Figure 1.7: Endothelial cell isolation from primary tissues 
1) Ulex lectin biotin complexes are bound to streptavadin Dynabeads. 
2) A single cell suspension is obtained by dissociating primary tissue using collagenase. It’s 
important to note that the purity of the extraction is dependent upon successfully obtaining a single 
cell suspension. Contamination of the single cell isolate can occur if other cells are bound to the 
endothelial cells.. 
3) The Ulex lectin binds to endothelial cell-specific glycosylation, which can be pulled out of the 
suspension using the magnetic dynabeads. These cells can be lysed to provide RNA for 
downstream molecular genetic analyses (original diagram). 
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1.5 Hypotheses and Aims 
As mentioned earlier in this thesis, McCall et al. (30) identified a number of miRNAs 
that were expressed specifically in endothelial cells when compared to other 
hematologic cells. However their findings from microarrays were not validated 
experimentally to confirm the expression patterns and biological relevance. 
Moreover to date there have been no analogous reports in the scientific literature 




1) To identify non-protein coding RNAs that are differentially expressed between 
tumour and healthy tissue associated endothelial cells. RNAseq was used to 
profile endothelial cells from a variety of tumour types, namely colorectal 
carcinoma, non-small cell lung cancer and renal cell carcinoma. 
 
2) To identify non-protein coding transcripts which are expressed solely in 
endothelial cells. This was facilitated by the use of quantitative PCR (qPCR) to 
compare the expression of the candidates (from the bioinformatic analysis) in non-
endothelial cell types. The additional sequencing of endothelial cell depleted bulk 
tissue was also used to help identify potential endothelial-specific candidates, 
through the elimination of genes that were more likely to be expressed ubiquitously. 
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3) The final aim of this project was to determine whether any of the non-coding 
RNA molecules identified during this project have relevance to angiogenesis and 
endothelial cell biology. In the case of PCAT19, this aim was achieved through 
acumen cell cycle analysis. 
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Chapter 2: Methods 
A table of materials and their sources can be found in Appendix 1 
2.1 Generation and analysis of RNAseq data 
SOLiD4 RNAseq (Figure 2.1) data was analysed to identify differentially expressed 
ncRNA, Herbert (53) had previously generated the data. The data was derived from 
a single set of a patient matched colorectal cancer and healthy colon associated 
endothelial cells. Illumina (Figure 2.2) data derived from non-small cell lung cancer 
and healthy lung associated endothelial cells as described by Herbert (53) was 
subsequently compared to the SOLiD4 data. The analysis of these two datasets 
allowed for the identification of any non-protein coding RNA molecules that were 
differentially expressed in both lung and colon tumour associated endothelial cells. 
The RNA from renal cell carcinoma associated endothelial cells (RCCEC) 
and healthy kidney associated endothelial cells (HKEC) were obtained (and the 
isolate purity confirmed by qPCR) from three patients (staging information can be 
found in Appendix 2) by Joseph Wragg as described by Mura et al (54). 
Furthermore RNA was obtained from the ‘endothelial cell depleted bulk healthy 
kidney tissue’ for all three patients. The 9 sets of RNA were Poly-A selected, 
barcoded, pooled and paired-end deep sequenced across two lanes on an Illumina 
HiSeq2000 by the Beijing Genomics Institute in Hong Kong, which produced 90bp 
(base pair) reads from 160bp fragments. In total, this experiment produced four 
files (~2.8 gigabytes (GB) of data each) per condition, per patient (forward and 
reverse reads from two lanes). The codes for the tuxedo pipeline used to analyse 
the data (~100 GB in total) can be found in Appendix 3. 
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Figure 2.1: SOLiD system of sequencing 
RNA is fragmented, converted into cDNA and ligated to adapter sequences (5’ adaptor - fragment 
1-adaptor - fragment 2 - 3’ adaptor) to form a mate-paired library, which is used for the emulsion 
PCR, bead enrichment and sequencing by ligation: 
1. The 5’ adaptor on the cDNA fragments is ligated to magnetic beads; 
2. Clonal amplification of the cDNA construct by emulsion PCR; 
3. Polystyrene beads are ligated to identify beads with successfully amplified constructs; 
4. Attachment of beads to a glass slide; 















6. Hybridisation of a di-base probe (spanning two nucleotides) to the cDNA fragment; 
7. Ligation of the di-base probes to the universal primer; 
8. Measurement of fluorescent dye attached to the probe; 
9. The fluorophore is cleaved from the probe and washed away; 
10. Steps 6-9 are repeated a total of 10 times; 
11. Denature the read from the cDNA; 
12. Five different reads are generated by offsetting the primer by one nucleotide per read (original 
diagram). 
 
Figure 2.2: Illumina sequencing system 
Following the fragmentation of RNA, cDNA is produced, size selected and attached to adaptors. 
The cDNA library is bound to a sequencing chip. ‘Clonal clusters’ are then produced by PCR based 
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bridge amplification. This process results in many clusters of reads for each cDNA molecule bound 
to the slide. Images are captured after every base (with a reversible dye terminator) is incorporated 
into the DNA fragment (original diagram). 
 
2.2 Tissue Culture 
Collagenase type I was used to isolated HUVEC from umbilical cords that were 
obtained (after informed consent) from the Birmingham Women’s Hospital (local 
ethics number: 11T063). HUVEC were cultured in vitro using Medium 199 (M199), 
which as supplemented with 10% (v/v) foetal bovine serum, 4 mM L-glutamine, 
200 units/mL of Penicillin-Streptomycin, 90 μg/mL heparin and bovine brain extract, 
as described by Maciag et al. (55). 
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% (v/v) foetal 
bovine serum, 4 mM L-glutamine, 200 units/mL of Penicillin-Streptomycin was 
used to culture the other cell types. Namely, HEK293T (human embryonic kidney 
293T cells), human dermal fibroblasts (DF), human aortic smooth muscle cells 
(HASMC) and keratinocytes (Ker). 
Both the supplemented DMEM and M199 were filtered using 0.22 μM pore 
bottle top filters, warmed to 37°C before use and stored at 4°C. All the cells were 
plated onto sterile 10 cm plates  (pre-coated with 0.1% w/v sterile gelatin in PBS 
for HUVEC) and maintained at 37°C with 5% CO2 in a humidified incubator. Once 
the cells reached confluence they were passaged at a 1:3 ratio (1:5 for the 
HEK293T). To split the cells they were incubated with 3 mL-1% (v/v) trypsin-EDTA 
after being washed with sterile PBS. Once detached the cells were centrifuged at 
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room temperature and 195 g for 5 minutes. The pelleted cells were resuspended in 
the appropriate media and divided equally between the new plates.  
 
2.3 RNA isolation and cDNA production 
Alan Zhuang provided total RNA from isolated liver tumour (hepatocellular 
carcinoma) associated endothelium (TLE) and healthy liver associated 
endothelium (HLE) as described by Mura et al. (54). Total RNA was obtained from 
HUVEC, dermal fibroblasts (DF), human aortic smooth muscle cells (HASMC) and 
keratinocytes (note, a low RNA yield prevented the analysis of all the genes in 
keratinocyte by qPCR) using a Qiagen RNeasy mini kit according to the 
manufacturer’s instructions. It is important to note that the optional DNase I 
digestion was also performed (qPCR confirmation of the efficiency of this step can 
be found in Appendix 4). The quality and quantity of the RNA was confirmed using 
a NanoDrop Spectrophotometer and Steve Kissane obtained a RIN (RNA integrity 
number) using a RNA Bioanalyser. 
The total RNA from all the cells was used to produce cDNA for the gene 
expression analyses. The cDNA reaction was performed as specified by the 
manufacturer’s instructions for the High Capacity cDNA Archive kit with random 
primers. Each cDNA reaction contained 500 ng of RNA per 20 μL reaction mix. 
Following the production of cDNA a serial dilution was conducted to prepare the 
cDNA for the qPCR reactions (1 in 20, 1 in 40, 1 in 80, 1 in 160 and 1 in 320). 
However traditional PCR was conducted using undiluted cDNA. 
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2.4 Universal Probe System (qPCR) 
Primers were designed using the web based Universal Probe Library (UPL) Assay 
Design Centre (primer sequences can be found in Appendix 5). Where possible all 
the amplicons span exon boundaries (snoRNA do not contain introns). Each 
universal probe qPCR (Figure 2.3) reaction mix contained: 12.5 μL 2x universal 
qPCR mix, 1 μL of each primer, 0.25 μL of the appropriate probe and 0.25 μL H2O. 
This mix was combined with 10 μL of cDNA (concentration as specified in Section 
2.3) in a different location to reduce the chances of contamination. The reactions 
were conducted on a Rotor-Gene RG-3000 qPCR machine using the following 
programme: 
Denaturation: 5 minutes at 95°C 
Denaturation: 15 seconds at 95°C 
Annealing and elongation: 45 seconds at 60°C 
Standard curves were generated using the serial dilutions of cDNA that 
facilitated the determination of the threshold position, which in turn allowed for the 
cycle threshold (CT) to be determined for each test cDNA (Appendix 6). The 
relative abundance of gene expression was then determined by comparing the CT 
value to the CT value of a housekeeping gene. FLOT2 (Flotillin 2) for inter-cell-





Figure 2.3 Universal probe system of qPCR 
The UPL system of qPCR relies upon small probes (8-9 nucleotides) that bind to multiple areas 
within the genome. Much like the TaqMan qPCR system, an adjacent quencher represses 
















fluorescent signal in a reaction, this occurs when a DNA polymerase destroys the probe when 
extending a primer, thereby separating the fluorophore from the quencher (original diagram). 
2.5 SYBR Green (qPCR) 
SYBR green (an asymmetrical cyanine dye) (Figure 2.4) was the method used in 
instances where a universal probe-binding site was not present within the target 
transcript (SNORD75, SNORD76 and SNORA81). SYBR green is less specific 
than the UPL system because of the potential for production of off target 
amplicons, which are fully capable of generating a fluorescent signal (unlike the 
UPL system, where the probe must be inside the amplicon to generate a signal). 
However an amplicon melt curve can be produced if a melt step is included in the 
qPCR programme, the presence of only one peak indicates that the reaction was 
specific. Each reaction mix contained: 12.5 μL 2x SYBR Green PCR mix, 0.5 μL 
10 μM primers, 2 μL H2O and 10 μL of cDNA. The following run settings were 
used: 
Denaturation: 5 minutes at 95°C 
Denaturation: 15 seconds at 95°C 
Annealing and elongation: 45 seconds at 60°C 
Melt: 1°C incremental increases from 55 to 99°C every 5 seconds, with the 






Figure 2.4: SYBR Green qPCR 
SYBR green fluoresces strongly only when bound within DNA and specifically binds to double 
stranded DNA by intercalating between nucleotides. Therefore a fluorescent signal is directly 
proportional to the amount of double stranded DNA in a reaction. The fluorescent signal will be 
greatest during the annealing or the extension steps of qPCR and will increase as more double 















2.6 Molecular Cloning 
PCAT19 was amplified from HUVEC cDNA (as prepared in Section 2.3) using 
PCR in five blocks (Figure 2.5) using a high fidelity (HF) DNA polymerase. A five 
block system was employed because PCAT19 contains many viral repeat regions, 
which inhibits the amplification of full length PCAT19 (note: even when PCAT19 
was inside the plasmid, it was not possible to amplify the full length molecule out 
of the plasmid). 100 μL mixes were set up for each of the five blocks, containing: 2 
μL 5x Phusion HF buffer, 2 μL 10 mM dNTPs (deoxynucleotides), 2 μL of forward 
primer, 2 μL reverse primer, 68 μL H2O and 2 μL of HUVEC cDNA (1380ng/μL). 
The PCR was performed as follows: 
Denaturation: 30 seconds at 98°C 
Denaturation: 10 seconds at 98°C 
Annealing: 30 seconds at 55°C  35 cycles 
Elongation: 1 minute at 72°C 
Elongation: 10 minutes at 72°C 
 It is important to note however that the parameters of the PCR reaction had 
to be changed for some of the blocks to improve the reaction efficiency. A 56°C 
annealing step was required for block one and three, and block two requires 2% 
DMSO (dimethyl sulfoxide). Once the blocks were amplified they were run on a 
1.5% agarose gel with SYBR Safe DNA Gel stain. Finally, the appropriate band 
was dissected and was purified using a Fermentas GeneJET gel extraction kit 
according to the manufacturer’s instructions. 
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Figure 2.5: PCR amplification of PCAT19 
Each of the blocks overlapped the adjacent block by 50bp (base pairs), with the exception of the 5’ 
end of block 1 (B1) and the three-prime (3’) end of block 5 (B5). The aforementioned blocks were 
amplified using primers that contained sequences from the lentivirus plasmid pWPI (15bp overlap) 
(original diagram). 
 
2.7 Plasmid Preparation 
All the plasmids required in this thesis were purified according the manufacturer’s 
instructions from cultures of E. coli using a Qiagen plasmid maxi kit or a GeneJET 
plasmid miniprep kit for either a large or small scale, respectively. Glycerol stocks 
were made from the bacterial cultures for long term storage, 500 μL of the positive 
cultures were mixed with 500 μL of sterile 30% (v/v) glycerol and stored at -80°C. 
In preparation for the Gibson assembly reaction (Section 2.8) the plasmid pWPI 
was linearized using the following mix: 5 μg of pWPI plasmid, 5 μL 10x New 
England BioLabs (NEB) restriction enzyme buffer 4, 2.5 μL PmeI and made up to 
50 μL with H2O. The digestion mix was incubated at 37°C for 1 hour. The 








slower than in their circular supercoiled form) using a GeneJET gel extraction kit 
according to the manufacturer’s instructions. 
 
2.8 Gibson Assembly 
To insert PCAT19 into pWPI (Figure 2.6) a Gibson assembly cloning kit was used 
(Figure 2.7), containing: 10 μL of PCR fragments and vector (20 ng of B1 and B5, 
40 ng of B2, B3 and B4 and 37.5 ng of linearized pWPI) in water, 10 μL 2x Gibson 
assembly master mix. The assembly mix was incubated for 50°C for 1 hour before 
being placed on ice in preparation for the transformation. The chilled product was 
added to a vial of NEB 5-alpha competent E. coli cells and mixed by flicking the 
tube 4 times and incubated on ice for 30 minutes. The bacteria were then heat 
shocked at 42°C for 30 seconds and transferred to ice for 2 minutes. 950 μL of 
room temperature Super Optimal broth with Catabolite repression (SOC) media 
was then added to the bacteria and incubated for 60 minutes at 37°C with vigorous 
shaking at 250 rpm. 100 μL of mixture was plated onto pre-warmed Luria broth 
agar plates, containing 50 μg/mL ampicillin. The plasmid preparation of positive 
colonies was conducted as described in Section 2.7. Sanger sequencing was 
conducted to confirm the sequence of PCAT19 from the selected colonies by the 
Functional Genomics, Proteomics and Metabolomics Facility (School of 
Biosciences, University of Birmingham, UK). 
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Figure 2.6: A plasmid map of PCAT19 in pWPI 
PCAT19 was cloned into pWPI, a 2nd generation bicistronic lentiviral vector. This vector allows 
enables the simultaneous expression of PCAT19 and EGFP (enhanced green fluorescent protein). 
The presence of an internal ribosome entry site allows EGFP to be independently translated into 
protein from the same mRNA molecule as PCAT19. This feature is essential because it allows for 
the isolation of positively transduced cells, but also because PCAT19 does not contain an open 





Figure 2.7 Gibson assembly of PCAT19 in pWPI 
The five PCAT19 blocks were assembled and inserted into pWPI using Gibson assembly. The 
reaction is facilitated by 5’ exonucleases that chew back the 5’ ends of the blocks and linear 
plasmid, which creates complementary binding sites. Once the DNA fragments annealed a DNA 
polymerase extends the 3’ ends to close any gaps at which point a DNA ligase seals the nicks 
(original diagram).  
 
2.9 Gene Overexpression 
The overexpression of PCAT19 in HUVEC was conducted using lentiviral 
transduction, which first requires the production of virus in HEK293T cells. 4.4 μg 
PCAT19 in pWPI (empty pWPI was used to generate lentivirus for the negative 
control), 3.3 μg psPAX2 and 1.3 μg pMD2G (9 μg plasmid DNA) was added to 1 
mL opti-MEM, to which 36 μL 1 mg/mL PEI (polyethylenimine) was added. The 
mixture was vortexed gently and incubated at room temperature for 10 minutes. 
The PEI/plasmid mixture was added to a 10 cm plate containing 3x106 HEK293T 
cells in supplemented DMEM (as described in Section 2.2) and returned to the 









virus) was then collected from the HEK293T cells and centrifuged at 195 g for 5 
minutes, supplemented with 8 μg/ml polybrene, 90 μg/ml heparin and bovine brain 
extract. The media was filtered with a 0.45 μm pore syringe filter before being 
added to a 10 cm plate containing 1x106 HUVEC. After 24 hours the media was 
replaced with fresh M199 and cultured as previously described in Section 2.2. One 
week later the successfully transduced EGFP positive cells were isolated using 
fluorescence-activated cell sorting by the University of Birmingham Flow 
Cytometry Facility. 
 
2.10 Acumen cell cycle analysis 
Eight wells (on a 96 well plate) per condition were seeded with 4000 HUVEC and 
allowed to settle for 24 hours. The media was then gently removed and replaced 
with 100 μL ice-cold 85% ethanol and incubated for 30 minutes at room 
temperature. The ethanol was gently removed and replaced with a 100 μ solution 
containing: 20 μL 10% triton X-100, 20 μL 10 mg/mL RNase A, 20 μL 1 mg/mL 
propidium iodide and 1940 μL 1x PBS. The plate was then covered with foil and 
incubated at 37°C for 20 minutes before being analysed by Ivette Hernandez-
Negrete using an Acumen Explorer TTP Lab Tech. 
 
2.11 siRNA transfection 
To knockdown PCAT19 in HUVEC, transfections were performed using siRNA 
(small interfering RNA). The siRNA were designed according to the guidelines 
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published by Reynolds et al. (56). To achieve this effect 1x106 HUVEC were 
seeded onto a 10 cm plate and left to settle for 24 hours. Two independent 
duplexes for PCAT19 and a negative control duplex (NCD) were used at a final 
concentration of 30 nM in 680 μL Opti-MEM per condition. The duplexes were left 
to incubate at room temperature for 10 minutes before being mixed with 108 μL 
(800 μL total) Opti-MEM containing 0.3% (v/v) RNAiMAX lipofectamine (pre-
incubated for 10 minutes at room temperature) and incubated at room temperature 
for an additional 10 minutes. During this incubation the media was removed from 
the HUVEC, which were subsequently washed with PBS twice and replaced with 
3.2 mL Opti-MEM to which the transfection mix was added. The HUVEC were 
incubated with this transfection mix for four hours in an incubator at 37°C and 5% 
CO2. Upon completion of this incubation the transfection mix was replaced with 
supplemented M199 (without antibiotics) and returned to the incubator for 48 hours, 
at which point the HUVEC were lysed and the RNA was extracted as described in 
Section 2.3. 
 
2.12 Two Colour Microarray analysis 
The RNA obtained from the HUVEC in Section 2.11 was used to produce two 
colour microarray data (Figure 2.8) by fluorescently labelling cDNA using a Quick 
Amp Labeling Kit (two-Colour) as per the manufacturer’s instructions. The cDNA 
was hybridized onto an Agilent human genome microarray chip (4x44K) and 
scanned by Steve Kissane at the University of Birmingham Genomics and 
Microarray Facility. The data obtained from this experiment was analysed using 
 39 
Bioconductor package Limma. The codes used to analyse the data can be found 
in Appendix 7. 
 
Figure 2.8 Determination of gene expression using two-colour microarray 
Two colour microarrays yields data in the form of relative fluorescent intensity to a reference per 
probe, i.e. the ratio of green fluorescence to red fluorescence. By comparing this ratio between 
different conditions (tested on another section of the same chip or on an entirely different chip) the 
differential expression a specific gene can be determined, providing that probes for the gene is 
present within the microarray chip (original diagram). 
 
2.13 Statistical Analysis 
All the wet lab experiments (as opposed to dry lab/bioinformatic) contained within 
this thesis were performed in triplicate unless otherwise stated and confidence 
limits present on graphs portray the standard error of the mean (SEM). The 











statistical significance of the data was determined using the Kruskal–Wallis one-
way analysis of variance (“*” was used to indicate that p = < 0.05), this test was 
used because it does not assume a normal distribution of data. 
The experiments requiring differential expression analysis utilised internal 
statistical analyses by the bioinformatics software. In the case of the RNAseq data, 
the significance (p value) of the differentially expressed transcripts was determined 
by Cuffdiff (a subprogram in Cufflinks from the Tuxedo pipeline) using Jensen-
Shannon divergence, a linear statistical model that measures the similarity 
between read abundances for each transcript per condition. For the microarray 
data, the significance (p value) was determined using the Limma package, through 




Chapter 3: RNAseq analysis of the colon vasculature 
3.1 Introduction 
This Chapter explores the use of RNAseq to identify non-protein coding RNAs in 
the vasculature of colorectal cancers. Currently the surgical resection of tumour is 
the ‘go to’ therapeutic option (57). However, only 80% of resections demonstrate a 
histologically clear margin and nevertheless 50% of those patients will relapse due 
to the presence of micro-metastases. It is for this reason that chemotherapy and 
other therapeutic agents have been given as adjuvant treatments for over 50 years. 
But metastatic colorectal cancer still carries a poor prognosis (58). Furthermore, 
insights into the growth of colorectal tumours could prove to be of importance to 
the health of society. 
The acquisition of a dedicated vasculature is imperative for cancer 
progression. All solid tumours require a blood supply to exceed two millimetres in 
diameter and metastasize (13). Moreover colorectal carcinomas are notable for their 
tendency to grow slowly and have a seemingly angiogenesis-dependent and 
progressive pattern of growth (8, 59). The identification of biologically relevant 
ncRNAs in the vasculature of colorectal cancer could yield novel therapeutically 
targetable pathways, or even act as biomarkers to guide treatment. 
The SOLiD platform was used to generate data, largely due to the 
availability of the platform ‘in house’. SOLiD data is generated and analysed in 
‘colourspace’ (Figure 3.1), rather than ‘basespace’ (Figure 3.2) where the reads 
are comprised of nucleotide sequences (52, 60, 61). 
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Figure 3.1: Decoding colourspace data. 
SOLiD relies on a two base pair probe system yet uses a four colour system to detect the 16 
combinations of bases. Each probe can bind and code for four different combinations of two 
nucleotides. Therefore multiple reads must be generated to determine which nucleotides are 
present in the sequence. Due to the use of colourspace, SOLiD platforms boast the lowest error 
rate (≤0.1) of all the NGS (next generation sequencing) platforms (52) (original diagram). 
 
 
Figure 3.2: Reading basespace data and the FASTQ format 
Basespace is used to store and analyse data from most NGS platforms (including Illumina) and 
refers to data that’s stored in a text-based format. One of the most common formats is FASTQ, 
which stores an identification code (A) for each read and a nucleotide sequence (B) with its 
corresponding quality score (C) (derived during base calling, which is described in Figure 2.2). The 
quality scores are recorded using the ‘American Standard Code for Information Interchange’ (from 































WXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~), where each symbol refers to the p value associated 
with the corresponding base in the nucleotide sequence (original diagram). 
 
3.2 Results 
The bioinformatic analysis of the SOLiD data from healthy and colorectal 
carcinoma associated endothelial cells, enabled the generation of a list of 
differentially expressed transcripts. Of the differentially expressed transcripts 
identified five were chosen to be validated using qPCR (Table 3.1). Two of the 
transcripts are antisense molecules to genes with well-defined functions. The other 
three genes are novel transcripts (these transcripts were assigned names and 
their sequences can be found in Appendix 8), which in the case of TECA1 
(theoretically endothelial cell associated) and TECA3, are derived from genomic 
locations not yet known to be transcribed. Whereas TECA2 is a novel 
mitochondrial DNA ‘readthrough’ (conjoined) transcript that incorporates many 
smaller known transcripts. 
  
Table 3.1: Tumour and healthy colon endothelium SOLiD RNAseq data 
The differential expression was determined using DEGseq. The data represents the fold change of 
‘raw read counts’. Three transcripts (TECA1, HNK1A-AS1 and TECA2) were expressed at greater 
Gene TE HE log2 (FC) Nucleotide
TECA1 78.3 0.4 6.5 XLOC_029144
HNF1A-AS1 112.0 26.0 2.1 NR_024345.1
TECA2 55639.9 35534.9 0.6 XLOC_032009
TP73-AS1 26.0 162.0 -2.6 NR_033708.1
TECA3 7.8 85.1 -3.4 XLOC_004164
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levels in the TE (tumour endothelium), whereas two transcripts (TP73-AS1 and TECA3) were 
expressed at greater levels in HE (healthy endothelium) 
 
TECA1 was highly expressed in HUVEC (Figure 3.3), which suggests that it 
could have a potential function in endothelial cells. However, there was no 
difference in expression between the TLE and HLE, which does not match the 
SOLiD4 differential expression data. HNF1A-AS1 (hepatic nuclear factor 1 alpha-
antisense 1) was observed to be expressed higher in the SOLiD4 data, however 
qPCR showed the opposite, it was expressed lower in TLE compared to HLE 
(Figure 3.4). Likewise TECA2 displayed a similar pattern, the qPCR results (Figure 
3.5) demonstrated lower expression in the TLE compared to HLE, which opposed 
the dynamic predicted from the NGS (next generation sequencing) data. 
Tumour protein 73-antisense 1 (TP73-AS1 or KIAA0495) was expressed to 
a greater extent in HLE compared to the other cells types (Figure 3.6). The 
upregulation of TP73-AS1 in HLE compared to TLE matched the expected pattern 
from the SOLiD data. TP73 was the only transcript that was consistently 
differentially expressed across the two experiments. TECA3 did not display a 
significant reduction in expression between TLE and HLE (Figure 3.7), which did 




Figure 3.3: The expression of TECA1 compared to FLOT2 




Figure 3.4: The expression of HNF1A-AS1 compared to FLOT2 
HNF1A-AS was mostly highly expressed in keratinocytes and was expressed to a lesser extent in 





































Figure 3.5: The expression of TECA2 compared to FLOT2 
TECA2 demonstrated higher expression in HLE compared to TLE and HUVEC, however the 
expression level in TLE was similar to HASMCs and keratinocytes (mean ±SEM). 
 
 
Figure 3.6: The expression of TP73-AS1 compared to FLOT2 
TP73-AS1 was significantly (p = < 0.05) differentially expressed in between the TLE and HLE. 




































Figure 3.7: The expression of TECA3 compared to FLOT2 
Of the six cell types profiled with qPCR, the keratinocytes had by far the highest expression of 
TECA3 (mean ±SEM). 
 
3.3 Discussion 
The use of raw read counts to display the data introduces some weaknesses to 
this dataset, as the counts are not normalised for the length of the transcript. This 
feature accounts for the massive read values for TECA2 compared to the other 
transcripts, as it is by far the longest transcript. Furthermore the transcript is 
produced by the mitochondria, which are quite abundant within cells. 
Notwithstanding these feature the fold change should still be accurate, yet the fold 
change between the TLE and HLE in the SOLiD4 and qPCR data did not match. A 
possible reason for this inconsistency could be due to the nature of the transcript, 
it is a read through RNA. Other transcripts produced in the same region could 
have biased the qPCR, however primers were chosen in an area not previously 















TECA2 could be an artefact produced by the mapping step of the NGS analysis, 
where multiple overlapping transcripts were mapped together into a single 
transcript incorrectly. SOLiD data is particularly susceptible to these errors 
because the data is generated in the form of very short reads (fewer than 50 base 
pairs). 
Furthermore TECA2 was not the only transcript to display inconstancies 
between the qPCR and NGS data. TECA1 and HNF1A-AS1 were also expressed 
at lower levels in the qPCR data and TECA3 showed very little change. These 
differences could be caused by the intrinsic differences between the endothelial 
cells within the colon and the liver. It is possible that qPCR would show the 
predicted expression pattern (from the SOLiD RNAseq data) if material from colon 
associated endothelial cells were used. Unfortunately no specimens were 
available at the time. As it stands TECA1 is probably the only transcript out of the 
four that warrants further investigation because the increased expression of 
TECA1 in HUVEC compared to the other cells hints at a potential function in 
angiogenesis. 
 However, whilst it would be worthwhile conducting qPCR on endothelial 
cells from colorectal carcinoma and patient matched healthy colon, the qPCR 
might still be inconsistent with the SOLiD4 data due to the lack of technical 
controls in the RNAseq experiment. It is also difficult to control for biological 
variation when using modern transcriptomic techniques to investigate the 
expression patterns of cells as endothelial cells due to the need to isolate them 
from the surrounding tissue. Especially considering that endothelial cells only 
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represent a small proportion of cells. Therefore the laborious nature of the isolation 
and size of the resected tissue is a severe limitation. Large samples are required 
to obtain relatively small amounts of RNA (8). In this vein the SOLiD4 experiment 
conducted by previous members of the Bicknell group did not control for variation 
between individuals. Whilst this is understandable, it does make the task of 
producing an accurate list of differentially expressed genes problematic, especially 
when combined with the lack of technical control (the two samples were patient 
matched, but were sequenced independently). 
In spite of its shortcomings this dataset has yielded a very interesting result, 
namely the expression pattern of TP73-AS1. TP73-AS1 has been observed to be 
supress oligodendroglial tumours and to induce Cisplatin (a chemotherapeutic 
drug) resistance in glioma cells after siRNA knockdown (62). This pattern lends 
support to the tumour suppressor-like expression pattern in colorectal and 
hepatocellular carcinoma-associated endothelial cells. It is especially interesting 
that the healthy endothelial cells displayed the highest expression levels of TP73-
AS1 out of all the cell types. Endothelial cells within their “normal” environment are 
usually quiescent; therefore it is consistent to see increased levels of tumour 
suppressor genes. Tumour Protein p73 (TP73) is of substantial interest to cancer 
researchers and has been seen to be mutated and downregulated in many types 
of cancer (63). Hence any potential regulation of TP73 by TP73-AS1 in endothelial 
cells would probably also be of considerable interest and is therefore worth future 
functional investigation by siRNA knockdown and in vitro angiogenesis assays 
(TP73-AS1 was not investigated further in this project due to time constraints).   
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Chapter 4: Enrichment of snoRNA in the tumour 
vasculature 
4.1 Introduction 
To improve the chances of successfully identifying differentially expressed genes 
in the tumour vasculature, the SOLiD4 data from Chapter 3 was cross-referenced 
with a second dataset. The second dataset was generated using Illumina 
sequencing, which has emerged to become the predominant NGS platform. 
Illumina sequencing has many advantages over the SOLiD platform. Not only is it 
technically simpler to conduct but also generates longer reads (> 90bp), which 
aids in the analysis of the data. This is incredibly important because it allows reads 
to span repetitive regions, which increases the number of uniquely mapped reads 
and therefore the genome (or transcriptome) coverage. Additionally, longer reads 
reduce the likelihood of SNPs (single nucleotide polymorphisms) or sequencing 
errors influencing read mapping (51, 52). 
Furthermore Illumina can be analysed by a greater number of mapping 
programmes, which allows for improvements based upon the advancements of the 
algorithms developed by the scientific community. Additionally, SOLiD data must 
be analysed in colourspace (as opposed to basespace), which requires a 
completely separate (and far more restrictive) set of tools to map the data to a 
colourspace reference. If colourspace reads are translated into basespace before 
being analysed a single sequencing error (or a SNP) can cause changes in the 




Figure 4.1: The impact of SNPs and errors on colourspace data 
1) Normal read sequence - The colourspace sequence is decoded using the last base of the 
sequencing primer as a starting point. Every nucleotide can then be decoded sequentially using the 
previous nucleotide and the colour of the di-base pair probe. 
2) Reads with sequencing errors - A single error will change not only one base when converted to 
basespace, but potentially all the nucleotides after the error. 
3) Reads containing SNPs - Reads when converted to basespace will have the same sequence as 
it’s target, but a single base pair mutation will cause a change of two numbers in the colourspace 
sequence (original diagram). 
 
4.2 Background information 
The Illumina data in question was derived from the endothelial cells associated 
with healthy lung tissue and solid lung tumour tissue. Lung cancer is the leading 
form of cancer mortality in the UK, it accounts for 21% of cancer deaths in women 
Target Sequence: TTGATGCAGCC 
 Probe Sequence: 
    Colourspace: T0123131230 
      Basespace: TTGATGCAGCC 
 
Target Sequence: TTGATGCAGCC 
    Colourspace: T0122131230 
      Basespace: TTGAACGTCGG 
 
Target Sequence: TTGACGCAGCC 
    Colourspace: T0121331230 





(rising year on year) and 24% in men (64). Although the rates vary drastically in 
different countries, worldwide lung cancer mortality accounts for ~18% of cancer 
deaths (65). Lung cancer can be separated into two main categories: small cell or 
non-small cell lung cancer (NSCLC). NSCLC accounts for over 80% of the lung 
cancer incidence (66), it was for this reason that NSCLC was used to produce the 
dataset discussed in this Chapter. There is a persisting need for novel therapeutic 
agents to be developed as lung cancer often presents in patients at an advanced 
stage, at which point surgery is often not possible. Moreover, current first line 
treatment regimes often add just over 2 months to the mean survival rates (67). 
Conjointly, the current anti-vascular therapies such as Bevacuzimab (anti-VEGF 
antibody) have been shown to be ineffective  (and sometimes less beneficial) in 
patients with squamous tumours (68). 
For the aforementioned reasons, the identification of differentially expressed 
ncRNAs between healthy and NSCLC associated endothelial cells could give 
productive insights into lung cancer pathology. However the experimental design 
shared some of the weaknesses of the colon data (as described in Chapter 3) and 
as a consequence of those weaknesses the two datasets were cross-referenced. 
This process involved the identification of the non-protein coding transcripts 
present in both datasets. Before determining which ncRNAs were differentially 
expressed and which transcripts displayed similar expression patterns in both 
datasets. This analysis yielded an unexpected result, the differentially expressed 
ncRNAs that were common to both the datasets were classified as snoRNA. 
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4.3 The function of snoRNA 
It has long been thought that the only purpose of introns was to serve as a buffer 
to protect exons from mutations, frame shift mutations in particular. However 
functional ncRNAs have been shown in the literature to be excised from some 
introns (69). One such type of these molecules are the snoRNAs (Figure 4.2). Three 
distinct classes of snoRNA have been identified to date. All three are involved with 
the posttranscriptional modification of RNA by guiding the functionality of distinct 
protein groups. 
 
Figure 4.2: Excision of snoRNA from host genes 
Following transcription of a gene, introns must be excised from pre-mRNA to produce mature 
mRNA.  Intron lariats are produced as a waste product of splicing exons together and are usually 
degraded. But if the intron contains secondary structures and/or sequence motifs they can be 
recycled to produce functional ncRNAs such as snoRNAs. Any genes that contain such RNA 





Box C/D snoRNAs (SNORD) are named because of the presence of C box 
(UGAUGA) and D box (CUGA) motifs that facilitate the binding to proteins that 
guide the 2’-O-ribose methylation of RNA (70). 2’-O-ribose methylation has been 
found to occur in functionally essential areas of the ribosome and splicesome, and 
prevents the editing of adenosine to inosine. The second group are the H/ACA box 
snoRNA (SNORA), which are defined by the presence of the H box (consensus 
ANANNA) and the ACA box (ACA). SNORA bind to a group of proteins and act as 
guides for pseudouridylation, which is the process of converting uridine to the 
‘universal base’ pseudouridine (Ψ/psi). The third member of the snoRNAs was 
only identified as a novel class of snoRNA in 2002, the small cajal body RNA 
(SCARNA) are capable of both pseudouridylation and 2’-O-methylation (70). For a 
review see refs. (69-72). 
 The snoRNA are, as their name suggests, restricted to the nucleus and 
SCARNA are further restricted to the cajal body, a subnuclear organelle. Of all the 
ncRNAs, snoRNA were among the earliest identified. It is perhaps because of their 
association of with the modification of ribosomal RNA that caused the functions of 
snoRNA to be seen as a relatively unglamorous area of research (72). However in 
recent years snoRNA have been subjected to a renewed interested because of the 
discovery that they are associated with alternative splicing, the formation of 
miRNA and an ever-expanding role in human disease. In point of fact, snoRNAs 
have recently been identified as being of consequence in the etiology of a diverse 





Following the analysis of RNAseq data derived from healthy and tumour 
endothelial cells in the lung and colon, seven snoRNA molecules were identified at 
greater levels in tumour endothelial cells (Table 4.1). The seven differentially 
expressed snoRNAs were comprised of one SNORA, one SCARNA and five 
SNORDs. The expression of the snoRNAs were validated and compared to the 
expression of their host genes using qPCR. Of the seven, SNORD75 (Figure 4.3), 
SNORD76 (Figures 4.4 and 4.5), SCARNA7 (Figure 4.6) and SNORA81 (Figure 
4.7) were confirmed using qPCR to be expressed at higher levels in TLE than HLE. 
SNORD32A (Figure 4.8), SNORD30 (Figure 4.9) and SNORD100 (Figure 4.10) on 
the other hand did not show the anticipated expression patterns. 
 
Table 4.1: Differentially expressed snoRNA in the lung and colon vasculature 
The RNAseq analysis yielded seven snoRNA that appeared to be differentially expressed in both 
lung and colorectal cancer (TE) compared to the healthy endothelium (HE). 
snoRNA Host%Gene TE HE FC TE HE FC
SNORD32A RPL13A 401.7 0.0 ∞ 567.7 26.5 3.1
SNORD30 SNHG1 107.7 0.0 ∞ 6053.9 374.5 2.8
SNORD76 GAS5 71.6 0.0 ∞ 4183.9 456.1 2.2
SCARNA7 KPNA4 67.8 0.0 ∞ 27.5 8.1 1.2
SNORD75 GAS5 128.5 3.5 3.6 140.2 7.2 3.0
SNORD100 RPS12 365.4 80.4 1.5 11744.0 3793.6 1.1




Figure 4.3: SNORD75 and GAS5 expression compared to FLOT2 
SNORD75 was most highly expressed in the TLE compared to the other cell types and was 
expressed at significantly higher levels when compared to the HLE. Furthermore SNORD75 was 
significantly upregulated compared to its host gene GAS5 (mean ±SEM). 
 
 
Figure 4.4: SNORD76 and GAS5 expression compared to FLOT2 
SNORD76 was most highly expressed in TLE and was expressed at significantly higher levels in 











































Figure 4.5: the enrichment of SNORD76 from GAS5 compared to SNORD75 
The expression of SNORD76 significantly eclipses the expression of not only GAS5, but also 
SNORD75 (mean ±SEM). 
 
 
Figure 4.6: SCARNA7 and KPNA4 expression compared to FLOT2 
SCARNA7 had a significant doubling of expression in TLE when compared to HLE. Furthermore 














































Figure 4.7: SNORA81 and EIF4A2 expression compared to FLOT2 
SNORA81 displays possible endothelial-specific patterns of expression in TLE and HLE when 
compared to DF and HASMC. Furthermore SNORA81 was significantly differentially expressed in 
TLE compared to HLE (mean ±SEM). 
 
 
Figure 4.8: SNORD32A and RPL13A expression compared to FLOT2 
SNORD32A was most highly expressed in the TLE and HLE compared to the other cell types, 
however the differential expression between the TLE and HLE was nominal. Furthermore there was 








































Figure 4.9: SNORD30 and SNHG1 expression compared to FLOT2 
The expression of SNORD30 was slightly upregulated in HLE when compared to TLE by qPCR. 
SNORD30 was most highly expressed in the TLE and HLE compared to the other three cell types. 
The expression of SNORD30 was slightly upregulated in HLE when compared to TLE. Furthermore 
there was only trace expression of the host gene SNHG1 compared to SNORD30 in all the cell 
types (mean ±SEM). 
 
 
Figure 4.10: SNORD100 and RPS12 expression compared to FLOT2 
SNORD100 was expressed at far higher levels in TLE and HLE compared to the other three cell 








































The results presented in this Chapter (when compared to Chapter 3) demonstrated 
an improved success rate with regard to identifying transcripts that were 
expressed at higher levels using both RNAseq and qPCR. The cross referencing 
of the two RNAseq datasets seems to have reduced the effect of some of the 
biological and technical variation. Although it is somewhat surprising that the 
snoRNAs featured so heavily in the differential expression lists following cross-
referencing. The upregulation in lung, colon and liver tissues indicate that these 
snoRNA could potentially be non-protein coding “pan” (all-inclusive) tumour 
endothelial cell markers. It does, however, indicate that comparing lung to colon 
endothelial cells has been at the expense of observing a wider range of gene 
classes that could have been upregulated in the endothelium of each individual 
tissue.  
Endothelial cells have been known to show transcriptional and functional 
differences between various tissues and organs (46). A characteristic difference in 
the lung is the predominance of non-sprouting (intussusceptive) angiogenesis, 
where endothelial cells proliferate to form a large lumen. The enlarged lumen is 
then split by the production of transcapillary pillars (columns formed of thickened 
endothelial cells) (18, 19). This process is markedly different to sprouting 
angiogenesis, which colorectal tumours rely upon heavily. These preferential 
mechanisms of angiogenesis, in conjunction with other factors could cause 
different gene expression profiles between the lung and colon endothelium. For 
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example, ROBO4 is upregulated specifically in the endothelial cells of many 
tissues, but is often absent in colorectal cancer associated endothelial cells (8). 
 The differences between the liver endothelium used for the qPCR and the 
tissues analysed by RNAseq is perhaps why SNORD32A, SNORD30 and 
SNORD100 appeared to have inconsistent levels of expression. It is possible that 
these three SNORDs are expressed at the predicted patterns in lung and colon 
endothelial cells, but not those of the liver. However, it is also possible that the 
differential expression for these three SNORDs is a result of unresolved technical 
variation. In point of fact, it is worrying that any snoRNA were detected in the 
RNAseq datasets. The methodology that was employed to generate the 
sequencing library should select specifically for the poly-A tailed RNAs from the 
total RNA (this dataset was originally generated to detect protein coding genes 
and poly-A selection can enhance the sequencing depth of mRNA by excluding 
classes of RNA such as rRNA). If this had been the case, the vast majority of the 
snoRNA would not have been sequenced because they are mostly derived from 
introns and therefore do not have poly-A tails (unless poly-A tails were specifically 
added following excision). Therefore, the fact that the snoRNA were detected 
indicates that there was a failure in the poly-A selection process and there is no 
guarantee that the selection failed to the same extent in each condition (hence the 
need for qPCR validation). 
Perhaps the most surprising feature of this project is the high expression of 
all the snoRNA in the TLE (and HLE to different extents) when compared to the 
expression in the other three cell types by qPCR. Moreover the expression does 
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not seem to be caused by the parallel differential expression of the host genes, 
rather by a specific maintenance (or excision) of the snoRNAs in the TLE and HLE.  
The relationship between SNORD75 and SNORD76, and their common host gene 
GAS5 provides support for this dynamic (Figure 4.3, 4.4 and 4.5). SNORD76 is 
enriched from GAS5 in the liver endothelium to a greater extent than SNORD75. 
While the reasons behind this are unknown, it is possible to say that the event is 
deliberate and cannot be due to differential splicing of the host gene (Figure 4.11), 
which would cause the opposite expression pattern. Moreover the lack of inclusion 
of the other snoRNA from GAS5 within the differential expression list gives 
anecdotal evidence that changes in the expression of GAS5 is not the cause of the 
enhanced enrichment of SNORD76. 
 
Figure 4.11: Alternative splicing of GAS5  
Of the two known GAS5 splice variants, only variant 1 (V1) can produce both SNORD75 and 
SNORD76. Whereas variant 2 (V2) is likely to be only capable of producing SNORD75 due to the 
inclusion of SNORD76 within the third exon (original diagram). 
 




Exon 2! Exon 3!V2!
SNORD75!
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The cause of the aforementioned mechanism is currently unknown, yet it is 
curious that it is not mimicked in HUVEC. If this phenomenon is unique to 
endothelial cells, it is at least only present in adult endothelial cells. The 
enrichment of the snoRNA is therefore probably a result of one of two causes. 
Firstly, the snoRNA are being deliberately excised in the liver associated 
endothelium (regardless of whether the snoRNAs serve a purpose or not). 
Secondly it could be a response to the cellular environment that is unique to the 
patients from which the patient matched tumour and healthy tissue was derived. 
One such cause of this type of response could be the anti-cancer therapies the 
patient was receiving at the time of surgery. The expression of snoRNA has been 
observed to change based upon cellular stresses such as ionising radiation (76), 
which is used in some cases as a treatment for cancer.  
Regardless of the mechanism by which the snoRNA are expressed in 
greater quantities in liver endothelial cells; SNORD75, SNORD76, SCARNA7 and 
SNORA81 are expressed higher in the tumour endothelium. As stipulated earlier, 
both SNORD75 and SNORD76 are derived from GAS5. It is interesting that they 
were observed to be expressed at higher levels in the tumour endothelial cells of 
three tissues considering that the most documented role for GAS5 is in tumour 
suppression. When downregulated GAS5 has been associated with tumours of 
poor prognosis and is generally upregulated in quiescent cells (78). However the 
activities of SNORD75 and SNORD76 could be independent of GAS5, indeed this 
idea does not contradict evidence from the scientific literature. Liao et al. (73) 
observed that SNORD76 was upregulated in NSCLC, which is one of the tissues 
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from which the endothelial cells were isolated for the NGS. Moreover GAS5 has 
other known functions to which SNORD75 and SNORD76 could be ascribed. One 
of these functions is in cellular starvation (78), which could result from the 
microenvironmental stresses that tumour endothelial cells are exposed to. Such 
microenvironmental stresses would be consistent with the qPCR for these snoRNA 
as the other cells were cultured and as such would have abundant nutrients. 
The functions of these four snoRNAs are not yet known. However they have 
been predicted to guide the modification of certain genes. SNORD75 and 
SNORD76 could guide the 2'O-ribose methylation of different locations within 28S 
rRNA. SNORA81 has also been predicted to guide the pseudouridylation of 28S 
rRNA. SCARNA7, on the other hand is predicted to guide the 2'O-ribose 
methylation of the U1 spliceosomal RNA (70, 79). It is possible that these snoRNAs 
are contributing to pathologically relevant changes within the proteome of tumour 
endothelial cells (and endothelial cells in general) through the above mechanisms. 
However it is also plausible that they are also functional by mechanisms as yet 
unknown. 
Out of the four differentially expressed snoRNAs (as determined by qPCR), 
SNORA81 was the most enriched in the endothelium compared to the other cell 
types. SCARNA7 also had low levels of expression in the non-endothelial cells and 
had the largest differential expression between the TLE and HLE (50% lower in 
HLE). It is for these reasons that SNORA81 and SCARNA7 look like particularly 
interesting candidates for further research. Nevertheless the differential expression 
patterns of all four of the snoRNA imply a possible angiogenic function and are all 
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worth further exploration of both their own function and their downstream 
implications, which could be employed as anti-angiogenic targets. 
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Chapter 5: RNAseq analysis of kidney cancer 
endothelium 
5.1 Introduction 
Endothelial cells can be highly specialised and be markedly different in different 
tissues and organs (46). This is certainly true in the kidney, where endothelial cells 
not only carry out their usual function, but can also form fenestrated capillary tufts 
in the glomerulus to filter blood and produce urine (80). Moreover, endothelial cells 
within the inner medulla of the kidney are exposed to a hyperosmolar 
hyperkalemic environment and very low oxygen levels (46). 
This functional difference makes renal cell carcinoma a prime target for a large-
scale genomic study to identify organ specific markers of the tumour vasculature.  
NGS has emerged as the preferred method of large scale genomic and 
transcriptomic characterisation. However, it is interesting to note that all too often 
little attention has been paid to the fundamentals associated with experimental 
design. Biologists have had the tendency to not treat NGS experiments as any 
other standard experiment with respect and close attention to controls and 
reproducibility (61). This has largely been due to the precedent set by earlier SAGE 
studies, like the work of St. Croix et al. (8), where it was not feasible to have 
replicates due to the cost and laborious nature of the studies. 
To an extent the rapid fall in the cost of NGS has precipitated more rigorous, 
well-designed and statistically robust experimentations. However, observational 
studies without biological and technical controls are common in the literature. The 
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Bicknell group published one such example of this: Zhuang et al. (81) is the only 
paper to date to utilise NGS technology to identify tumour endothelial cell markers. 
Zhuang et al. (81) utilised the SOLiD4 to probe the transcriptome of non-small cell 
lung cancer associated and adjacent healthy tissue associated endothelial cells, 
however it utilised the same methodology as the data presented in Chapter 3 of 
this thesis. As a result it suffers from the same lack of technical and biological 
controls. It was due to these deficiencies that the data was not used to select 
targets independently, but rather to confirm the selection of candidates from a 
more well-designed microarray experiment. Therefore, the power and advantages 
associated with the RNAseq data presented was restrained. RNAseq has by far 
more potential to identify novel targets than microarray data due to its non-targeted 
nature and ability to count discrete reads (as described in Chapter 1). This 
Chapter on the other hand adheres to a stricter canon with regard to data 
acquisition and analysis. Ultimately the data as presented will facilitate greater 
insights into the tumour endothelial transcriptome and will be sufficiently robust to 
stand independently, unlike the studies that have preceded it. 
 The availability of resected tissue that is large enough to allow for a 
sufficient number of endothelial cells to be isolated (and therefore RNA) is a great 
limitation. Especially when accounting for the laborious nature of the endothelial 
cell isolation. Nevertheless high quality RNA was obtained from renal cell 
carcinoma endothelial cells (RCCEC), healthy adjacent kidney endothelial cells 
(HKEC) and whole/bulk (endothelial cell depleted) kidney tissue (WNK). The three 
isolates from three patient-matched (tumour and healthy adjacent tissue) biological 
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replicates were barcoded (ligation of identifying nucleotide tags) and pooled 
directly after poly-A tail selection and RNA fragmentation (before library 
preparation). The multiplexing of the samples in this manner allows for the control 
of any bias that could be introduced during the reverse transcription, PCR 
amplification and sequencing. All 9 of the samples were then split across two 
Illumina HiSeq2000 lanes to enhance the read depth, without compromising the 
technical rigor (61). 
The inclusion of WNK is an important strength of this project when 
compared to the previous two Chapters. Any candidates that are found to be 
differentially expressed between the RCCEC and HKEC can be checked against 
the WNK. This feature allows for the quick exclusion of genes that are present at 
high levels in normal kidney cells and are therefore not endothelial cell markers. 
Moreover the fact that the WNK is made up of multiple patient matched cell types 
is an improvement upon the study by St. Croix et al. (8), which utilised non-patient 
matched isolated non-endothelial cells. 
 The bioinformatics pipeline used to conduct the analysis of RNAseq data 
can give wildly different results based upon the methods and algorithms they use. 
The ‘Tuxedo’ pipeline developed by Trapnell et al. (82) was employed to conduct 
RNAseq analysis. Tuxedo is a widely used (perhaps the most used) open-source 
pipeline and as such it has been tested extensively. Moreover, it is a fully 
connective pipeline that ensures excellent compatibility between the different 
stages of the analysis. Tuxedo is also a prime pipeline for this project because it is 
capable of tolerating more than two variables in a single differential expression 
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analysis. Tuxedo also has a number of advantages because its aligner ‘Tophat’ 
utilises the popular ‘Bowtie’ mapping tool, which is an ultrafast and memory-
efficient method of mapping to a Burrows-Wheeler indexed genome, the UCSC 
(University of California, Santa Cruz) GRCh37//hg19. Fundamentally this allows for 
the potential identification of novel genes and splice variants, which would not be 
possible using transcriptome mapping. 
 
5.2 Results 
CummeRbund was utilised to visualise the RNAseq data upon completion of the 
differential expression algorithms. Firstly, data from the three variables (RCCEC, 
HKEC an WNK) were compared to each other at the whole transcriptome level. 
Thereby grouping the variables based upon the similarity of their overall differential 
gene expression levels. Of the three variables, the gene expression levels were 





Figure 5.1: Phylogeny of the tumour vasculature 
The overall expression profile of all three samples demonstrates that RCCEC, HKEC and WNK 
were different to each other. The assignment of RCCEC to a separate ‘leaf node’ (branch) indicates 
that the gene expression profiles were more similar between HKEC and WNK, whereas more 
genes were differential expressed in RCCEC. This analysis suggests that the gene expression 
profile of RCCEC was affected by factors such as cellular environment, rather than the gene 
expression profile associated with cell type. 
 
 Secondly CummeRbund was used to generate a heat map (Figure 5.2), which 
allowed for the visualisation of the differential expression patterns of individual 
genes within the dataset as a whole. Importantly the heat map confirmed the 
presence of discrete gene clusters, some of which demonstrated specificity to 
each of the three variables. Cluster analysis was conducted using CummeRbund 
to reveal individual genes that displayed the expression patterns of interest. 
 The first cluster of interest queried (100,0,0) contained genes that were 
expressed at high levels in the RCCEC, but were absent (or only trace expression) 















specific genes were identified, one of which was classified as non-protein coding 
(LOC643733). By contrast, the second cluster probed (0,100,0) contained genes 
that were expressed at high levels in HKEC, but at lower levels in RCCEC and 
WNK (Table 5.2). This cluster contained a total of 12 genes that displayed a 
suppressive, healthy endothelial cell enriched expression pattern, one of which 
was classified as non-protein coding (H19). 
 The five most upregulated and downregulated non-protein coding transcripts 
in the RCCECs compared to the HKECs from the RNAseq data were also 
manually identified (Table 5.3). In which LOC643733 and H19 featured 
prominently along side multiple novel transcripts. Of these transcripts FLJ41200 
(LOC401492) also demonstrated potential tumour endothelial cell-specificity. 
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Figure 5.2 Cluster analysis of differentially expressed genes 
The heat map represents the log10 fold change of FPKM (fragments per kilobase of transcript per 
million mapped reads) per differentially expressed gene (red = high expression; white = low 
expression). There are distinct clusters of genes that are expressed preferentially in each of the 
three samples. The arrow highlights a gene cluster that appears to be specific to RCCECs. 
 
RCCEC HKEC WNK 
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Table 5.1: Strongly tumour endothelial specific genes 
This cluster of genes was significantly more highly expressed in RCCEC. The absolute expression 
of the genes in the three variables is displayed using ‘fragments per kilobase of transcript per 
million mapped reads’ (FPKM). 
 
RCCEC HKEC WNK
INSR 149.48 16.28 10.80
NDUFA4L2 102.46 12.14 13.38
INHBB 101.85 8.09 1.56
KCNE3 101.47 1.66 3.94
SERPINI1 97.76 7.54 10.04
CXCR7 95.75 6.35 6.39
TGFBI 95.67 6.35 13.24
SCARB1 90.41 5.17 3.52
MCF2L 84.94 16.97 6.75
ANGPTL4 84.25 7.05 9.30
LAMA4 74.61 8.41 3.63
MMP2 73.64 11.96 10.33
COL8A1 72.06 2.02 2.59
IL7R 70.73 3.47 7.73
KRT14,KRT17 70.12 2.05 4.27
LOC643733 68.13 14.24 3.44
C3 65.40 2.72 8.37
ANGPT2 65.30 4.36 1.48
MAGI1 62.66 9.61 11.64
TMCC3 60.45 10.59 5.97
PXDN 57.50 13.60 7.00
CHST15 56.58 8.82 4.49
NRP2 53.83 10.79 3.26




Table 5.2: Genes enriched in the healthy endothelium  
This cluster of genes was expressed at significantly levels in HKEC (FPKM). 
 
 
Table 5.3: Top significantly differentially expressed ncRNAs 
The top differentially expressed (red = high expression in RCCEC compared to HKEC; blue = low 
expression in RCCEC compared to HKEC) ncRNAs between RCCEC and HKEC were cross-




TIAM1 34.72 757.69 117.86
TFPI2 72.47 524.00 64.60
PMAIP1 119.61 516.07 118.07
PLAT 17.76 250.46 14.36
LRG1 2.92 200.51 27.28
IRF1 16.33 170.34 39.03
IL8 19.82 125.16 18.75
H19 27.94 114.92 41.53
IL6 16.65 108.71 25.77
ICAM1 10.96 96.46 11.35
GPM6A 4.03 81.04 17.10
FMO2 8.87 50.21 4.43
PCAT19 23.31 44.21 6.02
Gene FPKM
Gene Locus RCCEC HKEC log2 (FC) p value WNK
FLJ41200 chr9:13406378-13433075 47.80 0.26 -7.53 0.00005 0.16
XLOC_016373 chr22:17177801-17182186 22.63 1.18 -4.26 0.00005 0.81
LOC541471 chr2:111954254-112252884 45.69 6.98 -2.71 0.00050 13.51
DDX12P chr12:9549677-9600796 30.80 5.09 -2.60 0.00005 1.32
LOC643733 chr11:104772275-104789053 68.13 14.24 -2.26 0.00005 3.44
H19 chr11:2016405-2019065 27.94 114.92 2.04 0.00005 41.53
XLOC_002346 chr1:16567639-16568319 7.73 32.47 2.07 0.00005 20.05
XLOC_008708 chr15:56365833-56365983 20.48 108.61 2.41 0.01250 259.14
LOC553103 chr5:131628997-131731307 1.93 71.19 5.20 0.00005 84.29
XLOC_020105 chr5:169615221-169626215 0.24 27.82 6.87 0.00005 41.51
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5.3 Discussion 
The cluster analysis performed in this Chapter is not only a means of identifying 
interesting targets for further study, but also validates the RNAseq experiment as a 
whole. The majority of the genes identified through the cluster analysis were 
protein coding. Whilst the expression of protein coding genes is not of direct 
interest in this study, the scientific literature associated with those genes is more 
developed. Therefore if a cluster analysis designed to identify tumour endothelial-
specific genes actually identifies genes known to have those properties it is more 
likely that the read values accurately represent the transcriptome of the RCCECs, 
HKECs and WNK. 
 The majority of the genes identified by the cluster analysis when 
searching for tumour endothelial cells markers are indeed known to be involved 
with pathological angiogenesis associated tumour growth and progression. MMP2 
is particularly ‘eye catching’ as it has an extremely well established role in both 
physiological and tumour angiogenesis (83, 84) and was also identified by St Croix et 
al. (8). Additionally this list includes many other known genes that have been 
shown to be strong promoters of tumour angiogenesis including (but not limited to) 
INSR (8), CXCR7 (86), ANGPT2 (87) and PGF (88). Moreover and reassuringly, many 
of these genes have been used as targets for therapies in clinical trials (88-90).  
 The fact that LOC643733 was shown to have comparable expression to 
these genes through the cluster analysis is extremely encouraging (due to its low 
expression in HKEC and WNK, and relatively high expression in RCCEC) and is 
certainly worth further study. Thus far, LOC643733 (11q22.3) has not been the 
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subject of any functional studies, nor has it been associated with a tumour 
endothelial-specific expression pattern. However, it has been annotated by NCBI 
(National Center for Biotechnology Information) as being a Caspase 4, Apoptosis-
Related Cysteine Peptidase Pseudogene, which could be a clue to its potential 
function. As pseudogenes have been shown to play a role in protecting (acting as 
decoys) their namesakes and other genes from degradation by miRNA (91).  
 The strength of the tumour endothelial-specific cluster analysis also lends 
credibility to the endothelial cell-specific tumour suppressor analysis. The inclusion 
of H19 on this list is extremely interesting as it is one of the most well defined 
functional ncRNA in the scientific literature, and one of the earliest discovered (92-
94). H19 has been shown to be a tumour suppressor gene and mutations in H19 
have been associated with Beckwith-Wiedemann syndrome and Wilms 
tumourigenesis, which matches its suppressor profile in this RNAseq experiment. 
Despite its fame very little research has been conducted to determine the role of 
H19 in angiogenesis and endothelial cell biology and therefore, may be worth 
future study. 
Although it is possible to observe differences between variables using 
RNAseq, the data cannot directly prove the biological relevance of a gene. 
Therefore it is questionable whether RNAseq can be directly used definitively to 
prove a hypothesis (95). But the data presented in this Chapter gives the closest 
snap shot of the tumour endothelial cell transcriptome that is currently available. 
Further analysis of this dataset combined with follow-up in the laboratory could 
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lead to the discovery of coding and non-coding transcripts that have angiogenic 
and tumourigenic significance.  
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Chapter 6: The functional exploration of PCAT19  
6.1 Introduction 
Prostate Cancer Associated Transcript 19 (PCAT19) was highlighted as a 
potential endothelial cell-specific suppressor (due to it’s downregulation in tumour 
associated endothelial cells) using machine learning algorithms, specifically cluster 
analysis, to probe the RNAseq data described in Chapter 5 (Table 5.2). PCAT19 is 
classified as a long intergenic non-protein coding RNA (lincRNA), a class that up 
until recently has been dismissed as ‘junk’ (69). Coincidentally, the Bicknell group 
identified PCAT19 as a gene in 2000 (31) and confirmed its restriction to endothelial 
cells (31, 36). At that point in time PCAT19 was termed ECSM1 (Endothelial Cell-
Specific Molecule 1) because of its endothelial-specific expression pattern. 
However, the nomenclature was not accepted due to the prevailing assumption 
that transcripts lacking a substantive open reading frame were non-functional. It is 
perhaps because of the stigma attached to this RNA class that deterred research 
into the function of PCAT19. Moreover, the nomenclature rejection and the 
existence the similarly named ESM1 (also Endothelial Cell-Specific Molecule 1) 
effectively severed the link between this early functional insight and the gene it 
was attributed to. 
 In the intervening 15 years since the discovery of PCAT19 and the writing 
of this thesis, it has been renamed multiple times depending on the locus it was 
assigned to in the human genome. LOC100505495 was the most recently 
approved nomenclature. The change of nomenclature from LOC100505495 to 
PCAT19 was prompted by the publication of two strikingly large independent 
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genome-wide association studies (GWAS) in 2013 (96, 97). These studies profiled 
the genomes of 20,000 patients and identified PCAT19 as hosting the most highly 
associated SNP (Figure 6.1) with prostate cancer (including aggressive prostate 
cancer) and increased mortality of the patients (increased risk by 1.18). These two 
pieces of published information, in combination with the RNAseq cluster analysis, 
prompted the hypothesis that PCAT19 is functions as a suppressor endothelial 
cells. Of all the candidates identified in this study, PCAT19 was considered by the 
author to be the prime candidate with which to experimentally demonstrate the 
functional properties of ncRNAs in endothelial cells. 
 
Figure 6.1: PCAT19 contains a prostate cancer associated SNP 
The SNP rs11672691 (A/G substitution) is located within the second intron of PCAT19. Therefore it 
could potentially induce the production of different spice variants or create an alternative intragenic 
promoter (original diagram). 
 
6.2 Results 
A cluster analysis designed to identify potential endothelial cell-specific suppressor 
transcripts flagged PCAT19 as being restricted to endothelial cells and expressed 
at lower levels in RCCEC when compared to HKEC (Figure 6.2). The expression 
of PCAT19 in HKEC was roughly double that of RCCEC, which was mimicked in 






PCAT19 was shown by qPCR to be expressed at progressively greater levels in 
HUVEC as the cells approached confluence (Figure 6.4). 
 
Figure 6.2: RNAseq gene level plot for PCAT19 
The Illumina RNAseq data showed that PCAT19 was expressed at significantly (p = < 0.05) lower 
levels in WNK than both endothelial cell isolates, and was expressed at higher levels in HKEC than 
RCCEC (mean ±SEM).. 
 
 
Figure 6.3: PCAT19 is expressed to a lesser extent in TLE 
When normalised against FLOT2, PCAT19 was expressed at significantly (p = < 0.05) reduced 




































Figure 6.4: PCAT19 expression correlates with cell density 
PCAT19 when normalized against ACTB (house keeping gene) was expressed at significantly 
greater levels in HUVEC that were cultured at higher densities (mean ±SEM). 
 
 
Figure 6.5: Post-lentivirus transduction expression levels of PCAT19 
Virus containing empty (blank) pWPI plasmid and pWPI containing PCAT19 were exposed to 
HUVEC (separately). The transduction of PCAT19 under the control of the EF-1α promoter was 






































To explore whether the increase of PCAT19 in endothelial cells was of 
functional relevance in vitro, the expression levels of PCAT19 were increased in 
HUVEC using lentiviral transduction (Figure 6.5). Subsequently PI staining was 
conducted to facilitate cell cycle analysis using an Acumen cytometer on both the 
negative control (normal) HUVEC and the HUVEC transduced (overexpressing) 
with PCAT19 (Figure 6.6). The HUVEC containing elevated levels of PCAT19 
exhibited significantly (p = <0.05) higher levels of dead cells and cells undergoing 
apoptosis and a potential decrease in the proportion of HUVEC in G1 and G2/M 
phases of the cell cycle. 
 
Figure 6.6: The effect of PCAT19 on the cell cycle of HUVEC 
The histograms from Acumen cytometry data (8 replicates) demonstrates that HUVEC containing 
increased levels of PCAT19 are significantly (p = < 0.05) more prone to apoptosis and less likely to 
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To gain further insights into the molecular basis for this interaction, siRNA 
knockdown of PCAT19 was performed in HUVEC (Figure 6.7), the RNA from 
which was used to produce fluorescently labelled cDNA and hybridised to an 
Agilent microarray chip. The subsequent microarray analysis provided a list of 
genes that could be differentially expressed as result of the PCAT19 knockdown. 
Knockdowns using siRNA carry possibility of causing off-target effects that could 
modify gene expression independently of PCAT19. It was for this reason that two 
duplexes (designed to target different sequences within PCAT19) were used and 
by cross-referencing the differentially expressed gene lists, a number genes that 
could interact with PCAT19 were identified (Table 6.1). 
 
Figure 6.7:Confirmation of PCAT19 knockdown in HUVEC 
HUVEC were transfected with a NCD or a duplex (D1 or D2) designed to knockdown PCAT19, both 



















Table 6.1: Differentially expressed genes following the knockdown of PCAT19  
The two-colour microarray analysis (NCD versus each PCAT19 duplex) highlighted a number of 
differentially expressed genes. The seven genes listed in this table were chosen for their differential 
expression in both sets of HUVEC. 
 
The cDNA obtained from the overexpression studies was used to perform 
qPCR validation of the microarray data, any gene that was upregulated after the 
knockdown of PCAT19 should be downregulated by the overexpression of 
PCAT19 (and vice versa). WTAP (Figure 6.8) and HIST1H2BK (Figure 6.9) were 
upregulated following knockdown of PCAT19, but rather than being downregulated 
following the overexpression of PCAT19 their expression levels remained relatively 
constant. Of the five genes observed to be downregulated in the microarray 
analysis: CBX5 (Figure 6.10), SUMF1 (Figure 6.11) and ILII (IL-2) (Figure 6.12) all 
displayed increased expression levels, but only CBX5 was significantly 
differentially expressed. Whereas, CNN1 (Figure 6.13) and HMOX1 (Figure 6.14) 
did not display the predicted change and were expressed at lower levels following 




Duplex 1! Duplex 2!
WTAP! 0.74! 1.00! 0.000009!
HIST1H2BK! 1.08! 0.97! 0.000796!
CBX5! - 0.85! - 0.86! 0.000023!
SUMF1! - 0.99! - 0.86! 0.000022!
ILII! - 1.04! - 0.94! 0.000130!
CNN1! - 1.69! - 0.91! 0.000053!
HMOX1! - 0.88! - 1.73! 0.000005!
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Figure 6.8: WTAP expression when PCAT19 is overexpressed 
WTAP was not differentially expressed following the overexpression of PCAT19 (mean ±SEM). 
 
 
Figure 6.9: HIST1H2BK expression when PCAT19 is overexpressed 


































Figure 6.10: CBX5 is upregulated when PCAT19 is overexpressed 
CBX5 was expressed at significantly (p = < 0.05) increased following the overexpression of 
PCAT19 (mean ±SEM). 
 
 
Figure 6.11: SUMF1 expression when PCAT19 is overexpressed 






































Figure 6.12: ILII expression when PCAT19 is overexpressed 




Figure 6.13: CNN1 expression when PCAT19 is overexpressed. 

































Figure 6.14: HMOX1 expression when PCAT19 is overexpressed. 
The expression of HMOX1 was decreased following the overexpression of PCAT19 (mean ±SEM). 
 
6.3 Discussion 
The importance of the tumour vasculature in tumour progression provides a 
framework as to how a gene such as PCAT19 could have a significant correlation 
with aggressive prostate cancer. It is not yet known whether the SNP within 
PCAT19 impacts its function, but it may prime the endothelial cells to be more 
easily exploited by tumours. The development of vasculature is pivotal for the 
growth and metastasis of tumours, a tumour must acquire a blood supply to grow 
beyond ~2 mm in diameter (2, 92). 
PCAT19 also appears to affect the vasculature in a non-hereditary manner, 
through differential expression between the healthy and tumour endothelium. 
However, it is also not clear what causes the differential expression. The hijacking 
of blood vessels to supply a tumour requires many growth factors, each of which 
















network causes a host of microenvironmental changes, each of which is 
associated with the differential expression of genes (11, 12, 80, 98, 99). In this work 
PCAT19 was shown to be responsive to changes to the confluence of endothelial 
cells. The tumour endothelium is prone to being leaky and having loose cell 
boundaries when compared to healthy endothelium (10). A response to the loose 
cell boundaries between endothelial cells, which is akin to that of sparse HUVEC 
in which PCAT19 was expressed at lower levels, might be the cause of the 
differential expression of PCAT19. 
The low expresion of PCAT19 in the tumour vasculature and during the 
HUVECs transition from a quiescent state, to a state of relatively active replication, 
indicates that PCAT19 could have a role in proliferation. It was for this reason that 
PCAT19 was overexpressed in HUVEC. The ensuing cell cycle analysis 
demonstrated that when PCAT19 is expressed at greater levels in vitro, 
endothelial cells are more prone to be apoptotic. Moreover PCAT19 appears to 
allow more cells through G2/M into G1 (indicating that PCAT19 possibly influences 
the blocking of the G2/M checkpoint), however further testing would be required to 
confirm this (which is currently being carried out by members of Bicknell and Nagy 
groups at the University of Birmingham, including the effect of PCAT19 knockdown 
at different cell densities on HUVEC cell cycle). Overall, PCAT19s has the 
hallmarks of a tumour suppressor because of its effect on the cell cycle and its 
synchronous downregulation in tumour endothelial cells. This prospect is even 
more exciting because of the effective restriction of PCAT19 to endothelial cells. 
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Nevertheless the molecular mechanism by which PCAT19 enacts the 
aforementioned function is not yet known. It is possible that PCAT19 acts as a 
molecular sponge and protects other suppressors from miRNAs or other RNA 
decay pathways. But it could just as easily act as an epigenetic guide. The 
microarray analysis and subsequent qPCR validation described in this Chapter 
has provided useful hints towards this end. It is possible that PCAT19 interacts 
with heterochromatin protein chromobox homolog 5 (CBX5), also known as 
heterochromatin protein 1 (HP1) alpha (α), from 12q13.13 at the RNA level due to 
their significant co-expression observed in this study (overexpression of PCAT19 
is associated with higher CBX5 expression and knockdown of PCAT19 is 
associated with lower CBX5 expression). Furthermore, CBX5 is known to localise 
to heterochromatin during interphase and detach at the start of mitosis (100-101), the 
stage at which PCAT19 appears to have a functional affect according to the 
Acumen data. 
It is not yet possible to determine whether the interaction between CBX5 
and PCAT19 is direct or indirect, but RNA immunoprecipitation may provide an 
answer. Nevertheless, PCAT19 appears to influence the expression of CBX5, and 
the modulation of PCAT19 expression yielded similar functional outcomes in this 
study, when compared to the functional effect of CBX5 knockdown (when PCAT19 
and CBX5 expression is low growth arrest is more likely, and vice versa) (100). Lee 
et al (100) demonstrated that the depletion of CBX5 caused cell cycle arrest at the 
G2/M checkpoint through an interaction with BRCA1 (breast cancer 1). The 
aforementioned reasons raise the possibility that PCAT19 influences BRCA1 
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function indirectly through CBX5 (Figure 6.15). This prediction is also strengthened 
by the observation that PCAT19 has a tumour suppressor-like expression pattern 
(lower expression in healthy endothelium, than tumour endothelium). 
 
 
Figure 6.15: Predicted involvement of PCAT19 with the HP1-BRCA1 pathway 
CBX1 (HP1-β), CBX3 (HP1-γ) and CBX5 (HP1-α) have all been shown by Lee et al (100) to be 
independently (non-redundantly) important for the recruitment of BRCA1 to sites of double strand 
breaks. The depletion of CBX1, CBX3, and CBX5 expression, reduced the recruitment of BRCA1 to 
double strand breaks and caused defects in the homology directed repair (HDR) pathway and the 
arrest of the cell cycle at G2/M. Intriguingly, the depletion of these proteins also resulted in 
increased recruitment of the TP53BP1 (Tumour Protein P53 Binding Protein 1), which is involved in 
the non-homologous end-joining (NHEJ) pathway. If PCAT19 influences CBX5 expression, 


















pathways. In this model, PCAT19 enables the expression of CBX5, which allows the recruitment of 
BRCA1 to double strand DNA breaks (A). However, lower expression of PCAT19 would result in 
low CBX5 expression, which would block BRCA1 recruitment, and thereby promote the recruitment 
of TP53B1 (B) (original diagram). 
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Chapter 7: General Discussion 
The involvement of ncRNAs in angiogenesis is an area of increasing interest 
(Figure 7.1). Many ncRNA molecules have been identified in this thesis through 
the systematic analysis and the use of NGS technology. The computational and 
laboratory methods have formed the first concerted effort to demonstrate that 
ncRNAs are differentially expressed and potentially involved with pathological 
processes in tumour associated endothelial cells. The results obtained regarding 
PCAT19 alone effectively prove the hypothesis that was at the core of this thesis 
(‘functional non-protein coding transcripts are expressed specifically in endothelial 
cells’). PCAT19 shows restricted expression in the endothelium and is differentially 
expressed between healthy and tumour associated endothelial cells. Furthermore 
the modulation of PCAT19 in vitro causes functional changes in the in vitro cell 
cycle of endothelial cells and could thereby interfere with angiogenesis. 
 
Figure 7.1: Articles pertaining to “angiogenesis and non-protein coding RNA” 
In recent years there has been a spike in the number of articles in the field of angiogenesis and 
ncRNAs. Although it is concerning that only 46% of these articles are primary in nature, whereas 

































are review articles and 11% in the field of non-protein coding RNA (original diagram compiled using 
information from Scopus (102)). 
 
Traditionally the targeting of a protein (or protein product, e.g. glycosylation) 
has been seen as a prerequisite of any therapeutic intervention. In the case of 
tumour endothelial cell markers a desired therapeutic target would be localised in 
either the extracellular matrix or the plasma membrane. This protein location 
pattern when combined with the specific expression on the vasculature of tumours 
would therefore enable the systemic delivery of an anti-tumour endothelial cell 
agent without comprising the integrity of the healthy vasculature. One such 
example is vaccination against ROBO4 in mice, which limited tumour growth by 
stimulating the generation of anti-ROBO4 autoantibodies (34). The tumour 
endothelial-specificity of ROBO4 was essential to the targeting of this protein; as 
the targeting of less-specific markers using similar strategies could produce 
significant toxicity (due to the targeting of healthy vasculature). 
 However, in recent years there has been a surge in oligonucleotide-based 
therapeutics to target RNA in situ, over 30 of which have progressed into clinical 
trials (103, 104). Antisense DNA based oligonucleotides has been the most commonly 
employed strategy in these clinical trials. These antisense DNA based 
oligonucleotides specifically form a DNA-RNA heteroduplex with a the desired 
target, which in turn triggers the RNase H–dependent cleavage of the target (104). A 
variety of other strategies have also reached clinical trials including siRNA to 
degrade VEGF in liver cancer (105), snoRNA to initiate splicing modulation in 
Duchene Muscular Dystrophy and morpholinos (antisense DNA molecules, which 
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bind to the target RNA and block interactions with the RNA other molecules) to 
block translation in restenosis. The individual strategies employed by all of these 
studies are beyond the scope of this thesis, but comprehensive reviews regarding 
the targeting strategies, nucleotide modifications, toxicity and pharmacology of 
oligonucleotide-based therapies have been published by Bennett and Swayze (104) 
and Burnett and Rossi (105). 
 The RNA based strategies do share a number of advantages over 
traditional therapeutics. One of the largest advantages is that once a therapeutic 
target it identified, it is comparatively easier (and less costly) to design and 
manufacture an RNA based therapeutic than a protein/drug (104, 105). Furthermore 
the RNAs can be economically and reproducibly produced at a large scale for 
clinical use (105). 
On the other hand, RNA therapies have a number of weaknesses including 
the accumulation of unmodified RNAs in the kidneys. Even the encapsulation of 
RNAs in liposomes (or other nanoparticles) can result in their accumulation in the 
liver (105). Furthermore, upon entering cells the therapeutic effect is transient, and it 
is possible that the RNAs can trigger an innate anti-viral immune response. 
However, this risk can be reduced through the use of RNA modifications, such as 
2-thiouridine and 5-methylcytidine (106). RNA modifications are also necessary to 
prevent nuclease degradation in vivo (105). 
Nevertheless, Precedent for further use of oligonucleotide-based 
technologies for tackling vascular pathology has in part been set by the recent 
FDA (Food and Drug Administration) approval of drugs including Mipomersen. 
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Mipomersen is an antisense oligonucleotide based treatment for the 
cardiovascular disease dyslipidemia (an inherited genetic defect resulting in the 
elevation of cholesterol). Mipomersen acts by blocking the translation (through 
RNAase H degradation) of Apo B-100 mRNA at its site of synthesis in the liver. 
Mipomersen is a synthetic 20 bp long oligonucleotide that utilises a 
phosphorothioate backbone (the substitution of an oxygen atom with a sulfur atom) 
and 2’-O-(2-methoxyethyl) terminal modification to increase the stability and 
binding affinity of the molecule. The reported side effects of Mipomersen are mild-
to-moderate reactions at the injection-site and flu-like symptoms, which are 
considered to be tolerable. If these side effects were as a result of the therapy type 
(as opposed to targeting Apo B-100), e.g. a limited innate viral immune response, 
it bodes well for the use of this technology in the tumour vasculature (104, 107, 108). 
Such oligonucleotide-based therapies have been used to target ncRNAs (109) 
and could be developed to inhibit pathological angiogenesis and administered in 
conjunction with conventional chemotherapeutics (though not necessarily through 
the same delivery method). Especially considering all that is required is the 
production of a complementary oligonucleotide, which is trivial compared to the 
production of a specific antibody or small-molecule drugs. One concern is that the 
oligonucleotide-based therapeutics must enter into the cell to have the desired 
effect and intravenous mechanisms of delivery allow for the oligonucleotides enter 
cells indiscriminately, which could increase the likelihood of negative side effects. 
However, this would not necessarily be problematic when targeting ncRNAs such 
as LOC643733, which was predicted to be tumour endothelial cell-specific in this 
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study. The intrinsic non-toxic nature of RNA-based therapies indemnifies against 
toxic effects in cells that do not contain the target molecule (immunostimulation is 
a possibility, though not necessarily disadvantageous). Should LOC643733 be 
proven to promote pathological angiogenesis in RCCEC, the only effect of the 
oligonucleotide-based therapy would be to remove the effect of this promotion 
temporarily (104). The systemic risk to healthy cells could be limited through the 
injection of the oligonucleotide-based therapy directly into the tumour. Moreover if 
technologies were developed to enable the therapeutic delivery of large RNA/DNA 
molecules (103), suppressor genes such as PCAT19 or H19 could be delivered into 
the tumour endothelium to reduce its ability to proliferate. 
In conclusion, PCAT19 and the other non-protein coding transcripts 
identified in this study have the potential to be utilised in anti-angiogenic 
therapeutic interventions for solid tumours. At a minimum, the expression patterns 
of the transcripts identified within this thesis have contributed to the continuing 
understanding of cancer progression. The data in this thesis represents the first 
demonstration of lncRNA differential expression between tumour and healthy 
tissue associated endothelial cells, and the first time any ncRNAs have been 
shown to be specifically expressed in endothelial cells. Additionally, PCAT19 is the 
first endothelial cell specific ncRNA to have an experimentally demonstrated 
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Appendix 1: Table of materials 
 
Item Source Protocol 
Collagenase type V Sigma, UK Endothelial cell isolation 
Streptavidin-coated 
dynabeads 
Invitrogen, UK Endothelial cell isolation 
Biotinylated Ulex lectin Vector labs, US Endothelial cell isolation 
Hepatocellular carcinoma 
Queen Elizabeth Hospital, 
Birmingham 
Endothelial cell isolation 
Healthy liver tissue 
Queen Elizabeth Hospital, 
Birmingham 





Collagenase type Ia Sigma, UK HUVEC isolation 
Porcine skin gelatine Sigma, UK Tissue culture 
Medium 199 Sigma, UK Tissue culture 
Foetal calf serum 
PAA, The Cell Culture 
Co., UK 
Tissue culture 
Heparin Sigma, UK Tissue culture 
L-glutamine Sigma, UK Tissue culture 
Penicillin-Streptomycin Sigma, UK Tissue culture 
0.22 μm pore filters Millipore, DE Tissue culture 
Corning 10 cm plates Sigma, UK  Tissue culture 
PBS Sigma, UK Tissue culture, PI staining 
Trypsin-EDTA Sigma, UK Tissue culture 
Dermal Fibroblasts Promocell, DE Tissue culture 
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Keratinocytes TCS Cellworks , UK Tissue culture 
Human aortic smooth 
muscle cells 
TCS Cellworks , UK Tissue culture 
HEK293T 
Dr Mike Tomlinson, 
University of Birmingham 
Tissue culture 
DMEM Sigma, UK Tissue culture 
RNeasy mini kit Qiagen, UK RNA isolation 
2-mercaptoethanol Sigma-Aldrich, UK RNA isolation 
Ethanol Sigma, UK RNA isolation, PI Staining 
DNase I Qiagen, UK RNA isolation 
NanoDrop (NDT1000) 
Spectrophotometer 
LabTech,"UK RNA isolation and cloning 
High-capacity cDNA 
archive kit 
Invitrogen, UK cDNA production 
Primers Eurogentec, UK qPCR, PCR 
2x SYBR Green qPCR 
mix 
Invitrogen, UK qPCR 
2x Universal qPCR 
Mastermix 
Invitrogen, UK qPCR 
Nano Pure H2O n/a qPCR, PI staining. 
Universal Probe Library 
set, Human 





NEB, UK PCR 
dNTP Mix Bioline, UK PCR 
SYBR Safe DNA Gel 
stain 
Invitrogen, UK PCR, Plasmid preparation 
Rotor-Gene RG-3000 
qPCR machine 




Propidium iodide (PI) Invitrogen, UK PI Staining 
Ribonuclease A Sigma, UK PI Staining 
Bovine serum albumin Sigma, UK PI Staining 
Triton-X-100 BDH, US PI Staining 
Gibson Assembly Cloning 
Kit 
NEB, UK Molecular cloning 
Plasmid Mega Kit Qiagen, NL Plasmid preparation 
GeneJET plasmid 
miniprep kit 
Fermentas, US Plasmid preparation 
GeneJET gel extraction 
kit 
Fermentas, US Plasmid preparation 
PmeI NEB, UK Plasmid preparation 
pWPI Addgene, US 
Molecular cloning, 
lentiviral transduction 
psPAX2 Addgene, US Lentiviral transduction 
pMD2G Addgene, US Lentiviral transduction 
Opti-MEM Invitrogen, UK 
Lentiviral transduction, 
siRNA knockdown 
Human Embryonic Kidney 
293 cells 
ATCC, UK Lentiviral transduction 
Polybrene Sigma, UK Lentiviral transduction 
siRNA Duplexes Eurogentec, UK siRNA knockdown 
Lipofectamine RNAiMAX Invitrogen, UK siRNA knockdown 
Whole Human Genome 
Microarray Kit, 4x44K 
Agilent, US Microarray analysis 
Quick Amp Labeling Kit, 
Two-Color 
Agilent, US Microarray analysis 
Table S1: Table of materials 
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Appendix 2: Renal cell carcinoma patient information 
 
 
Table S2: Clinical and-pathological data for patients in the RNAseq analysis 
The tumour grade was recorded using the Fuhrman scale of I-IV, where patients with grade I 
tumours carry the best prognosis and grade IV the worst. The tumour staging is recorded using 
standard nomenclature: 
p - Primary tumour (p) 
T1a - limited to kidney <4 cm 
T2a - limited to kidney, >7 cm but not more than 10 cm 
T2b - limited to kidney, >10 cm 
Nx - Regional lymph nodes cannot be evaluated. 
  
ID Age Gender Tumour Type Tumour Grade Tumour Stage
1 70 Male Clear cell (cystic) 1 pT2a Nx
2 69 Female Clear cell 2 pT1a Nx
3 77 Female Clear cell 2 pT2b Nx
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Appendix 3: Kidney RNAseq analysis codes 
A3.1 Quality Checking reads from RNAseq data using FastQC 















# Run FastQC 
%%/FastQC/fastqc ${read_file_1} ${read_file_1P} ${read_file_2} ${read_file_2P} 
${read_file_3} ${read_file_3P} ${read_file_4} ${read_file_4P} ${read_file_5} 
${read_file_5P} ${read_file_6} ${read_file_6P} 
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A3.2 Map reads to the genome using Tophat 
# Tophat is a splicing aware aligner 




%%curl -O -L 
http://hgdownload.cse.ucsc.edu/goldenPath/hg19/bigZips/chromFA.tar.gz 
%%gunzip chromFA.tar.gz 
%%tar -xvf chromFA.tar.gz 
# To remove everything except chr1-22.fa, chrX.fa, chrY.fa and chrM.fa 
%%rm chr*_*.fa 
# Now concatenate (join together) all the files 
cat chr*.fa>hg19.fa 
 
# Index the genome 
%%cd /home/Klarke/Desktop/Genome_human 












3_L2\nreads_6P=WNK3_L2_P\ntophat2 -o ${reads_1}_tophat_out ${reference} 
${reads_1}.fq ${reads_1P}.fq\ntophat2 -o ${reads_2}_tophat_out ${reference} 
${reads_2}.fq ${reads_2P}.fq\ntophat2 -o ${reads_3}_tophat_out ${reference} 
${reads_3}.fq ${reads_3P}.fq\ntophat2 -o ${reads_4}_tophat_out ${reference} 
${reads_4}.fq ${reads_4P}.fq\ntophat2 -o ${reads_5}_tophat_out ${reference} 
${reads_5}.fq ${reads_5P}.fq\ntophat2 -o ${reads_6}_tophat_out ${reference} 
${reads_6}.fq ${reads_6P}.fq\nmv *_tophat_out* 
/home/Klarke/Desktop/Tophat_Data' > tophat2.txt 
 















tophat2 -o ${reads_1}_tophat_out ${reference} ${reads_1}.fq ${reads_1P}.fq  
tophat2 -o ${reads_2}_tophat_out ${reference} ${reads_2}.fq ${reads_2P}.fq  
tophat2 -o ${reads_3}_tophat_out ${reference} ${reads_3}.fq ${reads_3P}.fq  
tophat2 -o ${reads_4}_tophat_out ${reference} ${reads_4}.fq ${reads_4P}.fq  
tophat2 -o ${reads_5}_tophat_out ${reference} ${reads_5}.fq ${reads_5P}.fq  
tophat2 -o ${reads_6}_tophat_out ${reference} ${reads_6}.fq ${reads_6P}.fq  
mv *_tophat_out* /home/Klarke/Desktop/Tophat_Data 
 
# Unprotect the file 
%%chmod a+rw tophat2.txt 
# Make the text file excecutable 
%%chmod u+x tophat2.txt 
 




# You can also include the -r option (%%tophat2 -r 300 ${reference} ${reads_1} 
${reads_2}), which indicates the distance between the paired-end reads 
# therefore if the reads are 90bp and the fragment length is 480bp the code should 
be -r 300 
 
 






mapped_reads_6=WNK3_L2\nmkdir Desktop/Cufflinks_Data\ncufflinks -o 
cufflinks_${mapped_reads_1} 
Desktop/Tophat_Data/${mapped_reads_1}_tophat_out/accepted_hits.bam\ncufflin
ks -o cufflinks_${mapped_reads_2} 
Desktop/Tophat_Data/${mapped_reads_2}_tophat_out/accepted_hits.bam\ncufflin
ks -o cufflinks_${mapped_reads_3} 
Desktop/Tophat_Data/${mapped_reads_3}_tophat_out/accepted_hits.bam\ncufflin
ks -o cufflinks_${mapped_reads_4} 
Desktop/Tophat_Data/${mapped_reads_4}_tophat_out/accepted_hits.bam\ncufflin
ks -o cufflinks_${mapped_reads_5} 
Desktop/Tophat_Data/${mapped_reads_5}_tophat_out/accepted_hits.bam\ncufflin
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ks -o cufflinks_${mapped_reads_6} 
Desktop/Tophat_Data/${mapped_reads_6}_tophat_out/accepted_hits.bam\nmv 
*cufflinks_* Desktop/Cufflinks_Data' > cufflinks.txt 
 








#mkdir Desktop/Cufflinks_Data  
#cufflinks -o cufflinks_${mapped_reads_1} 
#Desktop/Tophat_Data/${mapped_reads_1}_tophat_out/accepted_hits.bam  
#cufflinks -o cufflinks_${mapped_reads_2} 
#Desktop/Tophat_Data/${mapped_reads_2}_tophat_out/accepted_hits.bam  
#cufflinks -o cufflinks_${mapped_reads_3} 
#Desktop/Tophat_Data/${mapped_reads_3}_tophat_out/accepted_hits.bam  
#cufflinks -o cufflinks_${mapped_reads_4} 
#Desktop/Tophat_Data/${mapped_reads_4}_tophat_out/accepted_hits.bam  
#cufflinks -o cufflinks_${mapped_reads_5} 
#Desktop/Tophat_Data/${mapped_reads_5}_tophat_out/accepted_hits.bam  
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#cufflinks -o cufflinks_${mapped_reads_6} 
#Desktop/Tophat_Data/${mapped_reads_6}_tophat_out/accepted_hits.bam  
#mv *cufflinks_* Desktop/Cufflinks_Data 
 
# Make the text file executable 
%%chmod u+x cufflinks.txt 
 
# Now we can assemble all of your data (this could take 12 hours) 
%%sh cufflinks.txt 
# Download the reference annotation from dropbox (up to date as of 05/2015): 
%% cd Desktop/Genome_human 









K3_L1/transcripts.gtf\ncufflinks_WNK3_L2/transcripts.gtf' > Cuff_assemblies.txt 
 









#Merge the assembled data 
%%cuffmerge -g ${annotation} -s ${reference} Cuff_assemblies.txt 
 
#Differential analysis with gene and transcript discovery 




%%cuffdiff -o Desktop/Final_outputs/Patient3/cuffdiff_out 










A3.4 Graphing with CummeRbund 
# Use the language “R” 
%%R 
# R codes start with: “>” rather than “%%” 
>library(cummeRbund) 
>setwd ("Desktop/Final_outputs/Patientall/cuffdiff_out") 
>cuff <- readCufflinks() 
 
A3.5 Example 1: Create a heatmap 
# Set the location and size of the output image 
>png(filename = '/home/Klarke/heatmapb.png') 
# To change the size use: >png(filename = '/home/Klarke/thinheatmap.png', width 
= 3000, height = 11000, units = 'px') 
# Choose the genes you want to use and transfer the gene_ids (XLOC numbers) 










# Write the data to the location entered above 
>dev.off()  
 
A3.6 Example 2: Plot data phylogeny 




A3.7 Example 3: Cluster Analysis 
# The following codes will list all the genes that have a similar expression pattern 
to the query. The numbers in brackets represent the expression (reads) desired 









A3.8 Example 4: Gene-level plots 
# The following codes will plot the expression levels of PCAT19 (LOC100505495) 














No. Colour Name Type 
1 
 
HUVEC 1:80 cDNA Unknown 
2 
 
HUVEC 1:80 cDNA Unknown 
3 
 
HUVEC 1:80 cDNA Unknown 
4 
 
HUVEC 1:80 no cDNA No Template Control 
5 
 
HUVEC 1:80 no cDNA No Template Control 
6 
 
HUVEC 1:80 no cDNA No Template Control 
7 
 
HLE 1:80 cDNA Unknown 
8 
 
HLE 1:80 cDNA Unknown 
9 
 
HLE 1:80 cDNA Unknown 
10 
 
HLE 1:80 no cDNA No Template Control 
11 
 
HLE 1:80 no cDNA No Template Control 
12 
 
HLE 1:80 no cDNA No Template Control 
13 
 
TLE 1:80 cDNA Unknown 
14 
 
TLE 1:80 cDNA Unknown 
15 
 




TLE 1:80 no cDNA No Template Control 
17 
 
TLE 1:80 no cDNA No Template Control 
18 
 
TLE 1:80 no cDNA No Template Control 
19 
 
Fib 1:80 cDNA Unknown 
20 
 
Fib 1:80 cDNA Unknown 
21 
 
Fib 1:80 cDNA Unknown 
22 
 
Fib 1:80 no cDNA No Template Control 
23 
 
Fib 1:80 no cDNA No Template Control 
24 
 
Fib 1:80 no cDNA No Template Control 
25 
 
ASM 1:80 cDNA Unknown 
26 
 
ASM 1:80 cDNA Unknown 
27 
 
ASM 1:80 cDNA Unknown 
28 
 
ASM 1:80 no cDNA No Template Control 
29 
 
ASM 1:80 no cDNA No Template Control 
30 
 
ASM 1:80 no cDNA No Template Control 
31 
 
Negative Control Negative Control 
32 
 
Negative Control Negative Control 
33 
 
Negative Control Negative Control 
Figure S1: No cDNA qPCR control 
During the production of cDNA from RNA, a control lacking MultiScribe (the cDNA production 
enzyme) was also generated. Without MultiScribe, no cDNA should be produced from the RNA and 
not produce fluorescence during the qPCR reaction. Through these means, it was possible to 
determine that the ‘on column’ DNA digestion successfully prevented genomic DNA contamination. 
This control was especially important for the reliable quantification of genes where an intron 
spanning qPCR amplicon was not possible, such as the snoRNAs (which are present in introns). 
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Appendix 5: Oligonucleotide Sequences 
Target Oligonucleotide Sequences (5’-3’) 
TECA1 Forward CAACAGCTTCTCAGTGATACAGG 
TECA1 Reverse AGTACACCCTGAAAACCCACA 
TECA2 Forward TTCTGGCCACAGCACTTAAA 
TECA2 Reverse TGGTTAGGCTGGTGTTAGGG 
TECA3 Forward GCGAATGTGCATATGACTGAA 
TECA3 Reverse CTCCATTGCCCCTTTTTATG 
HNF1A-AS1 Forward CATTCCCTTCTCTGGCGTAG 
HNF1A-AS1 Reverse AAAGTGGGCAGGGGGTAA 
TP73-AS1 Forward TCCGGCTTCCCTAAAGAGAG 
TP73-AS1 Reverse GGACACAAGGGAGGGTGAG 
SNORD76 Forward GCCACAATGATGACAGTTTATTTGC 
SNORD76 Reverse AGATAATGGTGGTTAAGATCCTCAT 
SNORD75 Forward AGCCTGTGATGCTTTAAGAG 
SNORD75 Reverse TTCAGAAATCCCTTCTGTCC 
GAS5 Forward AACTTGCCTGGACCAGCTTA 
GAS5 Reverse CAAGCCGACTCTCCATACCT 
SCARNA7 Forward TTGTGGTGGCTATGGAAAGG 
SCARNA7 Reverse AGCCTCAGATGCACTCCAAT 
KPNA4 Forward CAATGGAAACCATTCAGGAGA 
KPNA4 Reverse GAGGGCCCAGACTGTGTCTA 
SNORA81 Forward ATTGCAGACACTAGGACCATGT 
SNORA81 Reverse GGTCCACCCCAGTCTTTACA 
EIF4A2 Forward TGATCTACCTACCAATCGTGAAAA 
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EIF4A2 Reverse CCTTTCCTCCCAAATCGAC 
PCAT19 qPCR F GACACTGATACCAATGACATCCA 
PCAT19 qPCR R GCAGCAGAGTAGGTCAGGAAA 
CBX5 qPCR F AGAAGATGAAGGAGGGTGAAAA 
CBX5 qPCR R CCCGAGCGATATCATTG 
FLOT2 qPCR F TGTTGTGGTTCCGACTATAAACAG 
FLOT2 qPCR R GGGCTGCAACGTCATAATCT 
ACTB qPCR F CCAACCGCGAGAAGATGA 
ACTB qPCR R CCAGAGGCGTACAGGGATAG 
PCAT19 Cloning 1F ACTAGCCTCGAGAAACGTTATTTGACTGGAGTGAGG 
PCAT19 Cloning 1R TGTAATATTGGCATTGACATG 
PCAT19 Cloning 2F AATGAGAGAGACGGGAAG 
PCAT19 Cloning 2R AAGGAAAGCATATTGAAAATATAC 
PCAT19 Cloning 3F AATTGAAGTTGACTTTATGGAG 
PCAT19 Cloning 3R AGAATAGTGATTGGCCATATAG 
PCAT19 Cloning 4F TAAACATCTAGTCCAAAATTACTTG 
PCAT19 Cloning 4R CTAATTCGGCTCTTACAATC 
PCAT19 Cloning 5F TTCACCCCAACCTCCCTG 
PCAT19 Cloning 5R ATTCCTGCAGCCCGTAGTTTAAACTTCTGAAGTACAAACAT 
PCAT19 siRNA D1 GGGTAATCTGGAAGAGTTT 
PCAT19 siRNA D2 CAATGGAGGAAGAGGGTAA 
Table S3: Oligonucleotide sequences 
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Appendix 6: Differential expression qPCR data 
	  
	  
Table S4: Differential expression data (qPCR screening of different cell types) 





Table S5: Differential expression data (qPCR analysis of sparse HUVEC) 
The mean fold change for PCAT19 at each of the cell densities is displayed in this table (n=3). 
 
Gene TLE NLE HUVEC DF ASMC Ker Figure
TECA1 1.03:(0.07) 1.09:(0.14) 144.82:(11.88) 0.10:(0.00) 2.32:(0.21) 1.32:(0.07) 3.3
HNF1ABAS1 1.04:(0.06) 3.22:(0.31) 1.76:(0.17) 0.02:(0.00) 0.06:(0.00) 5.88:(0.28) 3.4
TECA2 0.93:(0.04) 2.84:(0.27) 1.09:(0.17) 0.29:(0.04) 3.38:(0.29) 4.56:(0.29) 3.5
TP73BAS1 1.03:(0.07 2.68:(0.30) 1.06:(0.11) 0.61:(0.04) 1.31:(0.17) 1.69:(0.18) 3.6
TECA3 0.93:(0.08) 1.22:(0.27) 0.63:(0.05) 1.73:(0.06) 2.27:(0.22) 18.60:(0.68) 3.7
SNORD75 0.85:(0.08) 0.50:(0.04) 0.05:(0.01) 0.12:(0.01) 0.54:(0.04) n/a
GAS5 0.40:(0.02) 0.12:(0.01) 0.05:(0.01) 0.10:(0.01) 0.28:(0.03) n/a
SNORD76 1.00:(0.02) 0.59:(0.03) 0.05:(0.01) 0.26:(0.03) 0.41:(0.05) n/a
GAS5 0.00:(0.00) 0.00:(0.00) 0.00:(0.00) 0.00:(0.00) 0.00:(0.00) n/a
SNORD76 1.0:(0.02) 0.59:(0.03) 0.05:(0.01) 0.26:(0.03) 0.41:(0.05) n/a
SNORD75 0.00:(0.00) 0.00:(0.00) 0.00:(0.00) 0.00:(0.00) 0.00:(0.00) n/a
GAS5 0.00:(0.00) 0.00:(0.00) 0.00:(0.00) 0.00:(0.00) 0.00:(0.00) n/a
SCARNA7 0.82:(0.09) 0.38:(0.05) 0.03:(0.01) 0.09:(0.01) 0.03:(0.01) n/a
KPNA4 0.15:(0.01) 0.05:(0.00) 0.04:(0.00) 0.15:(0.00) 0.15:(0.00) n/a
SNORA81 0.95:(0.03) 0.67:(0.06) 0.01:(0.00) 0.02:(0.00) 0.01:(0.00) n/a
EIF4A2 0.03:(0.01) 0.03:(0.00) 0.01:(0.00) 0.03:(0.01) 0.02:(0.00) n/a
SNORD32 1.00:(0.00) 1.11:(0.04) 0.06:(0.00) 0.47:(0.02) 0.21:(0.01) n/a
RPL13A 0.01:(0.00) 0.01:(0.00) 0.00:(0.00) 0.01:(0.00) 0.01:(0.00) n/a
SNORD30 0.87:(0.08) 1.11:(0.05) 0.07:(0.01) 0.15:(0.01) 0.28:(0.01) n/a
SNHG1 0.00:(0.00) 0.00:(0.00) 0.00:(0.00) 0.00:(0.00) 0.00:(0.00) n/a
SNORD100 1.14:(0.10) 1.63:(0.04) 0.19:(0.01) 0.07:(0.00) 0.25:(0.02) n/a
RPS12 0.12:(0.00) 0.19:(0.01) 0.09:(0.00) 0.07:(0.01) 0.08:(0.01) n/a










Gene Confluent*HUVEC*(3x10^6) Sparse*HUVEC*(1.5x10^6) Sparse*HUVEC*(7.5x10^5) Sparse*HUVEC*(3.75x10^5) Figure





Table S6: Differential expression data (qPCR validation of microarray data) 
The mean fold changes for all of the genes validated using qPCR after the PCAT19 knockdown 
(microarray data) are displayed in this table (n=3). 
 
 
Table S7: Differential expression data (qPCR validation of PCAT19 siRNA) 




Gene HUVEC)with)blank)pWPI HUVEC)with)pWPI)and)PCAT19 Figure
PCAT19 1.00)(0.12) 176.38)(10.40) 6.5
WTAP 1.02)(0.10) 1.13)(1.13) 6.8
HIST1H2BK 1.07)(0.07) 1.12)(0.12) 6.9
CBX5 1.11)(0.09) 1.68)(0.11) 6.10
SUMF1 1.69)(0.37) 2.27)(0.43) 6.11
ILII 0.85)(0.15) 1.03)(0.08) 6.12
CNN1 1.02)(0.14) 0.82)(1.10) 6.13
HMOX1 0.93)(0.05) 0.51)(0.05) 6.14
Mean)fold)change)relative)to)ACTB)and)normalised)to)blank)pWPI)(SEM)
Gene NCD D1 D2 Figure
PCAT19 0.965(0.07) 0.275(0.01) 0.365(0.05) 6.7
Mean5fold5change5relative5to5ACTB5and5normalised5to5NCD5(SEM)
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Appendix 7: Two Colour Microarray Analysis Codes 
%% R 
> library(limma) 
> targets <- readTargets("~/Desktop/ECSM1 Microarray analysis/targets.txt") 
> RG <- read.maimages(targets, path="~/Desktop/ECSM1 Microarray analysis", 
source="agilent.median") 
> RG <- backgroundCorrect(RG, method="normexp", offset=16) 
> MA <- normalizeWithinArrays(RG, method="loess") 
> MA.avg <- avereps(MA, ID=MA$genes$ProbeName) 
> design <- modelMatrix(targets, ref="wt") 
> fit <- lmFit(MA.avg, design) 
> fit2 <- eBayes(fit) 
> output <- topTable(fit2, adjust="BH", coef="kd", number=44000) 
> write.table(output, file="~/Desktop/ECSM1 Microarray analysis/Output.txt", 
sep="\t", quote=FALSE) 
# Type 'q()' to quit R. 
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Appendix 8: Novel colon sequences: 































































































A8.3 XLOC_004164 (TECA3): 
ACGCAAGTGGGGTGAAAAAAAAGGATACGCGAATGTGCATATGACTGAATAG
GGAGGAAGGTCAGGGCTAGAAAGGAGGCTACATAAAAAGGGGCAATGGAGA
GTGCACAGGAAAGACACAGGA 
 
